Nano Drugs

Supplementary Material Complete Listing of Results:
Tables SM.1 and SM.2 include complete listings of all the potential nanomedicine
products identified through the described research methods. Also included are the specific
details gathered for each of these products. Blank cells indicate that the information was not
available or not applicable. These databases served as the basis for the categorical analyses
described in this study.
Table SM.1. Potential nanomedicine therapeutic products.
ID
References
Nanomedicine
Relevance
Product Name or ID
Listed Company / Sponsor
FDA Classification
Condition / Application
Therapeutic
Identified Nanostructure
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
FDA Application Number or

Foreign Country
Administration Route
In Vivo Targeting
In Vivo
Use
Hard / Soft
Nanoparticle
Bawa, Han
Confirmed
Diprivan
Zeneca Pharma
Drug
Anesthetic
Propofol
Emulsion
150-200
Approved
Oct-89
019627
Intravenous
NA
In Vivo
Soft
NCT00332462, Garca-Gallont
Confirmed
Neoral
Novartis Pharmaceuticals
Drug
Liver Transplantation
Cyclosporine
Emulsion
10-150
Approved
Jul-95
050716
Oral
NA
In Vivo
Soft
Wagner, Project, Bawa, Faraji,

Papahadjopoulos, Bao
Confirmed
Doxil
OrthoBiotech
Drug
Kaposi Sarcoma
Doxurubicin
Liposome
87
Approved
Nov-95
050718
Intravenous
Passive
In Vivo
Soft
Wagner, Bawa, Griese
Confirmed
DaunoXome
Gilead Sciences
Drug
Kaposi Sarcoma
Daunorubicin Citrate
Liposome
45
Approved
Apr-96
050704
Intravenous
Passive
In Vivo
Soft
Wagner, Bawa, Faraji
Confirmed
Amphotec
SEQUUS Pharmaceuticals Inc.
Drug
Aspergillosis
Amphotericn B
Lipid Nanoparticle
115
Approved
Nov-96
050729
Subcutaneous
NA
In Vivo
Soft
Confirmed
AmBisome
Gilead Sciences
Drug
Fungal Infections
Amphotericn B
Liposome
45-80
Approved
Aug-97
050740
Intravenous
Passive
In Vivo
Soft
Wagner, Faraji, NCT00556946,

Ichikawa
Confirmed
Visudyne
QLT / Novartis
Drug
PDT Sensitizer
Verteporfin
Liposome
100
Approved
Apr-02
021119
Intravenous
Passive
In Vivo
Soft
Wagner, Project, Bawa, Faraji,

Wiedenmann
Confirmed
Abraxane
Abraxis BioScience
Drug
Breast Cancer
Paclitaxel
Protein Nanoparticle
130
Approved
Jan-05
021660
Intravenous
Passive
In Vivo
Biodegradable
9
10
NCT00912574, O'Hagan
NCT00406341
Confirmed
Confirmed
Focetria
Durezol
Sirion Therapeutics, Inc.
Biological
Drug
Vaccine Adjuvant
Anterior Uveitis
Vaccine
Difluprednate
Emulsion
Emulsion
165
110
Approved
Approved
May-07
Jun-08
European Union
022212
Intravenous
Topical
NA
NA
In Vivo
In Vivo
Soft
Soft
Influenza A (H1N1) pandemic vaccine suspension. Administered intravenously.

Difuprednate ophthalmic emulsion. Topically administered anti-inflammatory.
11
NCT00769093, Li
Confirmed
Ferumoxytol
AMAG Pharmaceuticals, Inc.
Drug
Anemia
Iron Supplement
Nanoparticle
30
Approved
Jun-09
022180
Intravenous
NA
In Vivo
Hard
Iron oxide nanoparticle coated with a carbohydrate shell. Intravenous injection for the treatment of
iron-deficiency anemia in adult patients with chronic kidney disease
12
Shah, Hayashi
Confirmed
Liple
Mitsubishi Tanabe Pharma Corporation
Drug
Peripheral Vascular Disease
Palmitate Alprostadil
Emulsion
209
Foreign Approval
Nov-88
Japan
Intravenous
NA
In Vivo
Soft
13
Wagner, Bawa, Glck
Confirmed
Epaxal
Berna Biotech
Biological
Hepatitis A
Vaccine
Virosome
150
Foreign Approval
1993
40 Countries
Intramuscular
NA
In Vivo
Soft
14
Wagner, Mischler
Confirmed
Inflexal V Berna
Berna Biotech
Biological
Influenza
Vaccine
Virosome
175
Foreign Approval
1997
43 Countries
Intramuscular
NA
In Vivo
Soft
15
Faraji, Muggia
Confirmed
Evacet
The Liposome Company, Inc.
Drug
Ovarian Cancer
Doxurubicin
Liposome
150
Foreign Approval
2000
European Union
Intravenous
Passive
In Vivo
Soft
16
NCT01003288, Fox
Confirmed
Pandemrix
GlaxoSmithKline Biologicals
Biological
Swine-Origin Influenza A H1N1 Virus
Pandemrix
Emulsion
150-155
Foreign Approval
Sep-09
European Union
Intravenous
NA
In Vivo
Soft
17
NCT00364676, Talon
Confirmed
Alocrest
Hana Biosciences, Inc
Drug
Solid Tumors
Vinorelbine
Liposome
100
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
18
NCT01041235, AzayaTherapeutics
Confirmed
ATI-1123
Azaya Therapeutics, Inc.
Drug
Solid Tumors
Docetaxel
Liposome
60-80
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
19
Aleku, Li L, Silence Therapeutics
Confirmed
Atu027
Silence Therapeutics
Drug
Solid Tumors
siRNA
Liposome
120
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
20
NCT00765973, Talon
Confirmed
Brakiva
Drug
Solid Tumors
Topotecan
Liposome
100
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
21
Bawa, NCT00689065, Heidel
Confirmed
CALAA-01
Calando Pharmaceuticals
Drug
Solid Tumors
siRNA
Polymeric Nanoparticle
50-80
Investigational
Phase I
Intravenous
Transferrin
In Vivo
Biodegradable
Cyclodextrin-containing siRNA delivery nanoparticles based on Calando's RNAi/Oligonucleotide

Nanoparticle Delivery (RONDEL) technology. Nanoparticle binds to transferrin receptors. Small
interfering RNA (siRNA) disrupts cancer gene expression. Intravenous delivery.
22
Flamel
Confirmed
FT-105
Flamel Technologies
Drug
Diabetes
Insulin
20-50
Investigational
Phase I
Intravenous
NA
In Vivo
Biodegradable
FT-105 is Flamel's next generation basal insulin. Phase I results suggest that FT-105 has the
potential to offer substantially better glucose control than currently-marketed long-acting insulins.
23
Pevion, Huckriede
Confirmed
HIV Vaccine
Mymetics / Pevion Biotech Ltd
Biological
HIV
Vaccine
Virosome
100-200
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
HIV vaccine based on the same virosome technology platform as Berna Biotech. Administered
intravenously. One of six virosome-based vaccines in clinical development for Pevion Biotech Ltd.
24
Flamel
Confirmed
IFN alpha-2b XL
Flamel Technologies
Biological
Hepatitis B/C, Cancer
Interferon Alpha-2b
20-50
Investigational
Phase I
Intravenous
NA
In Vivo
Biodegradable
IFN alpha-2b XL is a long-acting native interferon alpha-2b for the treatment of Hepatitis B and C
and some cancers.
25
NCT00364143
Confirmed
IHL-305
Yakult Honsha Co., LTD
Drug
Solid Tumors
Irinotecan
Liposome
100
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
Liposomal irinotecan and floxuridine. Licensing CPX-1 from Celator Pharmeceuticals (see below).
26
NCT00860522, Chang
Confirmed
JVRS-100
Juvaris BioTherapeutics, Inc.
Drug
Leukemia
Immunostimulatory DNA
Liposome
120
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
Lipid-DNA complex that is being developed as a therapeutic and an adjuvant to treat multiple
diseases. When combined with disease-specific antigens, JVRS-100 is capable of activating
substantial antibody- and cell-mediated immune responses. Intravenous injection.
27
NCT00024492, Neopharm
Confirmed
LE-M
NeoPharm, Inc.
Drug
Solid Tumors
Mitoxantrone
Liposome
<200
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
Liposomal mitoxantrone HCL (Novantrone). Based on NeoPharm's proprietary NeoLipid liposomal

formulation. Intravenously injected anti-cancer chemotherapy agent.
28
NCT00747474, Huang, TLC
Confirmed
Lipotecan
Taiwan Liposome Company
Drug
Solid Tumors
Camptothecin
Liposome
180-200
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
29
NCT01052142, Herringson
Confirmed
Lipovaxin-MM
Lipotek Pty Ltd
Biological
Melanoma
Vaccine
Liposome
240
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
30
Hamaguchi, Matsumura (2005),

Matsumura (2007)
Confirmed
MCC-465
Drug
Stomache Cancer
Doxorubicin
Liposome
143
Investigational
Phase I
Intravenous
GAH Antibody
In Vivo
Soft
31
NanoCarrier, Ino
Confirmed
NC-4016
NanoCarrier Co., Ltd.
Drug
Solid Tumors
Oxaliplatin
Micelle
50
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
32
NCT00445419, Pevion, Huckriede
Confirmed
PEV2
Pevion Biotech Ltd
Biological
Chronic Hepatitis C
Vaccine
Virosome
100-200
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
33
Pevion, Huckriede
Confirmed
PEV6
Pevion Biotech Ltd
Biological
Breast Cancer
Vaccine
Virosome
100-200
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
34
Confirmed
PEV7
Pevion Biotech Ltd
Biological
Recurrent Vulvovaginal Candidiasis
Vaccine
Virosome
100-200
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
35
Matsumura (2007), Seymour
Confirmed
PK2
Pharmacia & Upjohn Inc.
Drug
Liver Cancer
Doxorubicin
8.4
Investigational
Phase I
Intravenous
Galactose
In Vivo
Biodegradable
36
NCT01191775, Sheikhnejad
Confirmed
PNT2258
ProNAi Therapeutics Inc.
Drug
Cancer
Oligonucleotide
Liposome
100
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
37
NCT01054547, Ribeiro de Araujo
Confirmed
RVCLUV
University of Campinas, Brazil
Drug
Anesthetic
Ropivacaine
Liposome
130
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
38
NCT00385177, US Patent 7223770
Confirmed
SN2310
OncoGenex
Drug
Solid Tumors
SN-38
Emulsion
<200
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
39
NCT00927459, Rossi
Confirmed
TKM-ApoB
Tekmira Pharmaceuticals Corporation
Drug
Hypercholesterolemia
siRNA
Liposome
120
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
Stable-Nucleic-Acid-Lipid-Particles (SNALPs). Pegylated, liposomal delivery of small interefering RNA

(siRNA) for gene suppression in treatment of high cholesterol. Intravenously injected. Was PRO040201, but was renamed after initial studies were terminated.
40
NCT01519128, US Patent
20090176813
Confirmed
TMC278
Tibotec Pharmaceuticals Ltd
Drug
HIV
Nanosuspension
130
Investigational
Phase I
Intravenous
NA
In Vivo
Soft
Colloidal solutions containing non nucleoside reverse transcriptase inhibitors (NNRTIs), targeting
HIV-1 virus.
41
Bawa, NCT00455052,
Constantinides
Confirmed
XMT-1001
Mersana Therapeutics
Drug
Solid Tumors
Camptothecin
5-10
Investigational
Phase I
Intravenous
Passive
In Vivo
Biodegradable
42
Debbage, Dobrovolskaia, Schluep
Confirmed
CRLX101
Cerulean Pharma, Inc.
Drug
Solid Tumors
Camptothecin
78
Investigational
Phase I/II
Intravenous
Passive
In Vivo
Biodegradable
43
44
Flamel
NCT00271063, Booser
Confirmed
Confirmed
IL-2 XL
L-Annamycin
Flamel Technologies
Callisto Pharmaceuticals
Biological
Drug
Solid Tumors
Acute Lymphocytic Leukemia
Interleukin-2
Annamycin
Liposome
20-50
150
Investigational
Investigational
Phase I/II
Phase I/II
Intravenous
Intravenous
Passive
Passive
In Vivo
In Vivo
Biodegradable
Soft
45
NCT00964080, Matsumura (2007),

Mebiopharm, Sankhala
Confirmed
MBP-426
Mebiopharm Co., Ltd
Drug
Solid Tumors
Oxaliplatin
Liposome
180
Investigational
Phase I/II
Intravenous
Transferrin
In Vivo
Soft
Description / Additional Details

Liposomal propofol. General anesthetic administered intraveneously.
Cyclosporine nanoemulsion. Administered through oral solution or gel capsule. It is an
immunosuppressant used to prevent organ rejection in people who have received a liver, kidney, or
heart transplant.
Pegylated, liposomal doxorubicin. Anti-cancer chemotherapy drug administered through
intravenous injection. Used to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer,
and other solid tumors.
Liposome encapsulated aqueous solution of citrate salt of daunorubicin. Anti-cancer chemotherapy
drug administered through intravenous injection. Used to treat solid tumors.
Colloidal suspension of lipid-based amphotericin B. Subcutaneous delivery. Used to treat severe and
potentially life-threatening fungal infections.
Unilaminar, liposomal amphotericin B. Intravenous injection. Used to treat severe and potentially
life-threatening fungal infections.
Liposomal verteporfin. Photodynamic sensitizing agent. Drug is administered by intravenous
injection and collects in the abnormal vasculature in the back of the eye created by macular
degeneration. Drug is activated by short laser treatment, to destroy the abnormal vasculature.
Nanoparticle-albumin-bound paclitaxel (nab paclitaxel). Albumin is a human protein used to form
the nanoparticles. Anti-breast-cancer chemotherapy agent delivered through intravenous injection.
Palmitate alprostadil nanoemulsion intravenously injected for treatment of peripheral vascular

disease (PVD). Approved for use in Japan.
Hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenze virosomes (IRIV).
Intramuscular delivery. Licensed in over 40 countries.
Influenza vaccine adjuvanted with immunopotentiating reconstituted influenze virosomes (IRIV).
Intramuscular delivery. Licensed in over 43 countries.
Generic Doxil (see above).
Influenza A (H1N1) pandemic vaccine suspension. Administered intravenously. Approved by the
European Union.
Liposomal vinorelbine. Anti-cancer drug that inhibits mitosis at metaphase through its disruption of
microtubule assembly. Proprietary sphingomyelin/cholesterol liposome (OPTISOME) encapsulated
formulation. Intravenous injeciton.
Docetaxel in proprietary Protein Stabilized Nanoparticle (PSN) formulation. Anti-cancer
chemotherapy drug. Intravenous injection.
Silences lead internal RNAi therapeutic candidate, Atu027, is currently in a Phase I clinical trial.
Atu027 is a liposomal siRNA formulation targeting PKN3 for the treatment of advanced solid cancer.
Based on AtuPLEX platform.
Liposomal topotecan . Anti-cancer drug for treatment of refractory ovarian, small cell lung (SCLC),
and cervical cancers. Proprietary sphingomyelin/cholesterol liposome (OPTISOME) encapsulated
Liposomal camptothecin. Intravenously injected anti-cancer chemotherapy drug.

Liposomal formulation to deliver cancer antigens which produce an immunoresponse against the
cancer cells. Intravenously injected.
Targeted. MCC-465 is an immunoliposome-encapsulated doxorubicin (DXR). The liposome is tagged
with polyethylene glycol (PEG) and the F(ab)2 fragment of human monoclonal antibody GAH, which
positively reacts to >90% of cancerous stomach tissues, but negatively to all normal tissues. In
preclinical studies, MCC-465 showed superior cytotoxic activity against several human stomach
cancer cells compared with DXR or DXR-incorporated PEG liposomes
Micellar oxaliplatin.
Hepatitis C vaccine based on the same virosome technology platform as Berna Biotech.
Administered intravenously. One of six virosome-based vaccines in clinical development for Pevion
Biotech Ltd.
Breast cancer vaccine based on the same virosome technology platform as Berna Biotech.
Administered intravenously. One of six virosome-based vaccines in clinical development for Pevion
Biotech Ltd.
Vulvovaginal candidiasis vaccine based on the same virosome technology platform as Berna
Biotech. Administered intravenously. One of six virosome-based vaccines in clinical development for
Pevion Biotech Ltd.
Doxorubicin was linked via a lysosomally degradable tetrapeptide sequence to N-(2hydroxypropyl)methacrylamide copolymers bearing galactosamine. Targeting, toxicity, and efficacy
were evaluated in 31 patients with primary (n 25) or metastatic (n 6) liver cancer.
No additional details are readily available.
Ropivacaine (RVC) large unilaminar vesicles (LUV). Liposomal ropivacaine intravenously injected as
general anesthetic.
Nanoemulsion derivative of SN-38 (SN2310). Intravenously injected anti-cancer chemotherapy
agent.
Camptothecin conjugated with Mersana's proprietary Fleximer technology. Fleximer is a

biodegradable and bio-inert polymer that can be chemically linked to small molecules, biologics and
nucleic acids. Intravenously injected anti-cancer chemotherapy drug.
CRLX101 (formerly named IT-101) is a conjugate of camptothecin (CPT) and a linear, cyclodextrinbased polymer. IT-101 is designed to increase the exposure of tumor cells to the chemotherapeutic
drug while minimizing the toxic side effects.
IL-2 XL, is a second-generation long-acting interleukin-2.
Liposomal annamycin. Intravenously injected anti-cancer chemotherapy agent.
Transferrin targeted. MBP-426 is a novel oxaliplatin-encapsulated transferrin (Tf) -conjugated Nglutaryl phosphatidylethanolamine (NGPE)-liposome. MBP-426 demonstrated potent anticancer
preclinical activity and has recently entered clinical trials. Direct drug binding to Tf receptor (TfR)
was demonstrated in human cancer cells in vitro; the drug delivery is thought to be enhanced via
uptake by TfR.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Therapeutic
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
46
Matsumura (2009), NanoCarrier
Confirmed
Nanoplatin
NanoCarrier Co., Ltd.
Drug
Solid Tumors
Cisplatin
Micelle
20
Investigational
47
EpeiusBiotechnologies
Confirmed
Reximmune-C
Epeius Biotechnologies
Genetic
Solid Tumors
GM-CSF Gene
Nanoparticle
100
48
NCT00505713, EpeiusBiotech,
Morse
Confirmed
Rexin-G
Epeius Biotechnologies
Genetic
Solid Tumors
Rexin-G
Nanoparticle
49
Bawa, Starpharma
Confirmed
Vivagel
StarPharma Holdings
Drug
STD Prevention
SPL7013
50
Bawa, NCT00356980, Paciotti
Confirmed
Aurimmune (CYT-6091)
CytImmune Sciences, Inc.
Biological
Solid Tumors
51
NCT00245297, Powell
Confirmed
BAY 79-4980
Bayer
Drug
52
NCT00361842, Mayer
Confirmed
CPX-1
Celator Pharmaceuticals
53
NCT00875693, Mayer
Confirmed
CPX-351
54
Matsumura (2007), Thurston
Confirmed
55
NCT00646230, Okuda
56
57

Foreign Country
In Vivo Targeting
In Vivo
Use
Hard / Soft
Nanoparticle
Phase I/II
Intravenous
Passive
In Vivo
Soft
Investigational
Phase I/II
Intravenous
von Willebrand
factor
(Collagen-Binding)
In Vivo
Biodegradable
Combines Epeius proprietary targeted delivery system with a powerful immune-stimulating gene
that recruits and activates a patients own immune cells at the site(s) of residual metastatic
diseasewhich is the source of cancer recurrence.
100
Investigational
Phase I/II
Intravenous
von Willebrand
factor
(Collagen-Binding)
In Vivo
Biodegradable
Nanoparticle construct consisting of envelope, matrix, capsid, enzymes, and genetic therapeutic.
Preferentially targets the collagen of the tumor matrix and delivers gene therapy to the tumor site.
Intravenously injected.
Dendrimer
Investigational
Phase I/II
Topical
NA
In Vivo
Soft
Dendrimer gel for delivery of SPL7013. Dendrimers are small repeatedly branching polymeric
molecules. Topically administered vaginal microbicide for STD prevention (HIV and herpes).
TNF-alpha
Colloidal Gold
30
Investigational
Phase II
Intravenous
TNF-
In Vivo
Hard
Pegylated colloidal gold nanoparticles with surface bound tumor necrosis factor (TNF). TNF binds to
and activates tumor cell TNF receptors, which results in an increase in tumor cell apoptosis.
Haemophilia A
Kogenate FS
Liposome
80-110
Investigational
Phase II
Intravenous
NA
In Vivo
Soft
Liposomal formulation of Recombinant Factor VIII, a antihaemophilic factor synthesized through

recombinant DNA technology. Intravenously injected for Haemophilia treatments.
Drug
Solid Tumors
Irinotecan
Liposome
100
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Liposomal irinotecan and floxuridine. Combination of approved anti-cancer drugs, for enhanced
synergistic effects. Treatment of cancer, particularly GI tumors. Intravenous delivery.
Celator Pharmaceuticals
Drug
Acute Myeloid Leukemia
Cytarabine and Daunorubicin
Liposome
100
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Liposomal cytarabine and daunorubicin. Combination of approved anti-cancer drugs, for enhanced
synergistic effects. Treatment of cancer, particularly leukemia. Intravenous delivery.
EndoTAG-1
Medigene AG
Drug
Solid Tumors
Paclitaxel
Liposome
180-200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
EndoTAG-1 is a combination of positively charged liposomes with the therapeutic substance

paclitaxel embedded therein. The EndoTAG-1 concept is expected to provide a wide range of
applications. Principally, it could be suited for the treatment of all types of solid tumors which have
their own vascularization.
Confirmed
Fenretinide
CerRx Inc.
Drug
Neuroblastoma
Fenretinide
Emulsion
176
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
NCT01276548, Shimada
Confirmed
Genexol-PM
Samyang Pharmeceuticals
Drug
Solid Tumors
Paclitaxel
Micelle
10-200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
NCT00492141, Knight
Confirmed
L9NC
University of New Mexico
Drug
Solid Tumors
L9NC
Liposome
100-300
Investigational
Phase II
Aerosol
Passive
In Vivo
Soft
58
Jamil, NeoPharm
Confirmed
LE-DT
NeoPharm, Inc.
Drug
Solid Tumors
Docetaxel
Liposome
<200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
59
NCT01190982, Zhang
Confirmed
LEP-ETU
NeoPharm, Inc.
Drug
Solid Tumors
Paclitaxel
Liposome
150
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
60
NCT00104754, Zhang
Confirmed
LE-SN38
NeoPharm, Inc.
Drug
Solid Tumors
SN-38
Liposome
150-200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Liposomal SN38 (active agent in irinotecan). Based on NeoPharm's proprietary NeoLipid liposomal
formulation. Intravenously injected anti-cancer chemotherapy agent.
61
NCT00739466
Confirmed
Liposomal Alendronate
Biorest Ltd.
Drug
Coronary Artery Stenosis
Alendronate
Liposome
148-180
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Liposomal alendronate. Intravenously injected for treatment of coronary artery stenosis.
62
NCT00053716, US Patent 5980551
Confirmed
Liprostin
Endovasc, Inc.
Drug
Prostaglandin
Liposome
100-200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Liposomal prostaglandin. Intravenously injected for treatment of peripheral vascular disease (PVD).
63
NCT00144963, Talon
Confirmed
Marqibo
Drug
Solid Tumors
Vincristine
Liposome
100
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
64
Wagner, Bawa, Park
Confirmed
Myocet
Elan Corporation
Drug
Breast Cancer
Doxorubicin Citrate
Liposome
190
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
65
NCT01039103
Confirmed
Nanocort
Enceladus Pharmeceuticals BV
Drug
Rheumatoid Arthritis
Prednisolone
Liposome
<150
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
66
Chow, TLC
Confirmed
NanoVNB
Drug
Colon Cancer
Vinorelbine
Liposome
95.2
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
67
Bawa, Shah, Pannu, NanoBio
Confirmed
NB-001
NanoBio Corporation
Drug
Herpes
Multiple Formulations
Emulsion
180
Investigational
Phase II
Topical
NA
In Vivo
Soft
68
Koizumi, Zamboni
Confirmed
NK012
Nippon Kayaku Co. Ltd.
Drug
Solid Tumors
SN-38
Micelle
20
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
69
70
NanoCarrier, Negishi
Alexis, Matsumura (2004)
Confirmed
Confirmed
NK105
NK911

Drug
Drug
Stomache Cancer
Solid Tumors
Paclitaxel
Doxorubicin
Micelle
Micelle
85
30-50
Investigational
Investigational
Phase II
Phase II
Intravenous
Intravenous
Passive
Passive
In Vivo
In Vivo
Soft
Soft
71
NCT00038207, Gelmon
Confirmed
ONCO-TCS
Inex Pharmaceuticals
Drug
Solid Tumors
Vincristine
Liposome
120
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft

Micellar cisplatin.
Fenretinide emulsion for intravenous injection. Anti-cancer chemotherapy agent for treatment of
Neuroblastoma.
Micellar formulation of paclitaxel. Intravenously injected anti-cancer chemotherapy agent for
treatment of a variety of forms of cancer.
Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC). Anti-cancer chemotherapy agent.
Aerosolized for potential inhalation delivery.
Liposomal docetaxel. Based on NeoPharm's proprietary NeoLipid liposomal formulation.
Intravenously injected anti-cancer chemotherapy agent.
Liposomal paclitaxel. Based on NeoPharm's proprietary NeoLipid liposomal formulation.
Intravenously injected anti-cancer chemotherapy agent.
Liposomal vincristine sulfate. Anti-cancer drug that inhibits cell division by binding to tubulin in
mitotic spindles. Proprietary sphingomyelin/cholesterol liposome (OPTISOME) encapsulated
Liposomal doxorubicin. Intravenously injected anti-cancer chemotherapy agent. International
tradename is Caelyx.
Liposomal prednisolone. Intravenously injected to elicit anti-inflammatory response for treatment
of rheumatoid arthritis.
Pegylated liposome.
Nanoemulsion droplets based on proprietary NanoStat technology. Multiple drug formulations are
under clinical investigation. Treatment will be topically administered.
Micellar formulation of SN38 (active agent in irinotecan). Intravenously injected anti-cancer
chemotherapy agent for treatment of various cancers.
Micellar paclitaxel.
Micellar doxorubicin.
Liposomal vincristine. Intravenously injected anti-cancer chemotherapy agent for treatment of
various cancers.
Liposomal Lurtotecan. Intravenously injected anti-cancer chemotherapy agent for treatment of
various cancers.
Licensing CPX-1 from Celator Pharmeceuticals (see above).
72
NCT00046787
Confirmed
OSI-211
OSI Pharmaceuticals, Inc.
Drug
Solid Tumors
Lurtotecan
Liposome
100-200
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
73
NCT00940758
Confirmed
PEP02
PharmaEngine
Drug
Solid Tumors
Irinotecan
Liposome
100
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
74
Confirmed
PEV3
Mymetics / Pevion Biotech Ltd
Biological
Falciparum Malaria
Vaccine
Virosome
100-200
Investigational
Phase II
Intravenous
NA
In Vivo
Soft
75
Wagner, NCT00484120, Pharmos
Confirmed
Pharmos NE Cream
Pharmos Corporation.
Drug
Osteoarthritis
Diclofenac
Emulsion
100-200
Investigational
Phase II
Topical
NA
In Vivo
Soft
76
Matsumura (2007), Paul
Confirmed
PK1
University of Glasgow
Drug
Breast Cancer
Doxorubicin
Investigational
Phase II
Intravenous
Passive
In Vivo
Biodegradable
77
Davis, Alexis, Access Pharm
Confirmed
ProLindac
Access Pharmaceuticals, Inc.
Drug
Ovarian Cancer
DACH Platinum
6-15
Investigational
Phase II
Intravenous
Passive
In Vivo
Biodegradable
78
Wagner, NCT00460525,
MedicalNewsToday
Confirmed
RTS S/AS02
Biological
Plasmodium Falciparum Malaria
FMP2.1/AS02A
Liposome
20
Investigational
Phase II
Intramuscular
NA
In Vivo
Soft
Liposome delivered, genetic malarial vaccine.
79
Alakhov, Matsumura (2007),

Supratek
Confirmed
SP1049C
Supratek Pharma, Inc.
Drug
Solid Tumors
Doxorubicin
Micelle
30
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
Proprietary intravenous doxorubicin formulation developed for the treatment of cancers that are
otherwise resistant to doxorubicin. SP1049C is active in chemoresistant and metastatic cancers.
Potential opportunity exists for the treatment of metastatic adenocarcinoma of the upper
gastrointestinal tract as well as other chemo resistant indications including refractory colon, breast
and non-small cell lung cancers and leukemia.
Malaria vaccine based on the same virosome technology platform as Berna Biotech. Administered
intravenously. One of six virosome-based vaccines in clinical development for Pevion Biotech Ltd.
Diclofenac nanoemulsion delivered topically in a cream. Intended to provide anti-inflammatory
action for treatment of arthritis.
ProLindacTM is a prodrug of DACH platinum in which the cytotoxic agent is bound to a watersoluble
biocompatible copolymer backbone, called hydroxypropylmethacrylamide (HPMA).
Aerosolised L-CsA should suppress T-cell activation in the lung tissue and subsequently BOS
development.
STEALH liposomal cisplatin. Intravenously injected anti-cancer chemotherapy agent for treatment of
various cancers.
80
NCT01334892, Behr
Confirmed
L-CsA
PARI Pharma GmbH
Drug
Bronchiolitis Obliterans
Cyclosporine
Liposome
40-50
Investigational
Phase II/III
Inhalation
NA
In Vivo
Soft
81
NCT00004083, Newman
Confirmed
SPI-77
SEQUUS Pharmaceuticals Inc.
Drug
Solid Tumors
Cisplatin
Liposome
110
Investigational
Phase II/III
Intravenous
Passive
In Vivo
Soft
82
NCT00617981, Lindner
Confirmed
ThermoDox
Celsion Corporation
Drug
Solid Tumors
Doxorubicin, Lyso-Thermosensitive
Liposome
175
Investigational
Phase II/III
Intravenous
Thermosensitive
In Vivo
Soft
83
NCT00089180, Cafardi
Confirmed
Dimericine
Applied Genetics
Drug
Precancerous Condition
T4N5
Liposome
200
Investigational
Phase III
Topical
NA
In Vivo
Soft
Liposomal gene therapy intended to repair damaged DNA caused by UV overexposure on the skin.
Topical lotion is applied to the skin.
84
NCT00328692, Hosokawa
Confirmed
KW-3902
NovaCardia, Inc.
Drug
Heart Failure
Rolofylline
Emulsion
130
Investigational
Phase III
Intravenous
NA
In Vivo
Soft
Rolofylline emulsion intravenously injected for prevention of congestive heart failure.
85
Debbage, Shaffer
Confirmed
Opaxio
Cell Therapeutics, Inc.
86
87
Dobrovolskaia
Confirmed
Auritol (CYT-21001)
CytImmune Sciences, Inc.
Flamel
Confirmed
hGH
Flamel Technologies
Drug
Solid Tumors
Paclitaxel
Biological
Solid Tumors
Taxol and TNF-a
Colloidal Gold
Biological
Growth Disorders
HGH
5-100
Investigational
Phase III
Intravenous
Enzyme-Activated
In Vivo
26
Investigational
20-50
Investigational
Preclinical
Intravenous
TNF-
In Vivo
Hard
Preclinical
Intravenous
NA
In Vivo
Biodegradable
Intravenous
NA
88
Flamel
Confirmed
IFN beta XL
Flamel Technologies
Biological
Multiple Sclerosis
Interferon Beta
20-50
Investigational
Preclinical
89
Caruthers, Roszek
Confirmed
Perfluorocarbon Nanoparticle
Philips Medical Systems
Other
Atherosclerosis
Radionuclides
Perfluorocarbon NP
200-300
Investigational
Preclinical
90
Pevion, Huckriede
Confirmed
PEV4
Pevion Biotech Ltd
Biological
RSV
Vaccine
Virosome
100-200
Investigational
Preclinical
91
Canelas, Liquidia
Confirmed
PRINT
Liquidia Technologies
Drug
Drug Delivery Platform
200
Investigational
Preclinical
Intravenous
NA
Biodegradable
Thermally sensitive liposomal doxurubicin. Used in combination with radio frequency ablation
(RFA). Liposomes are delivered to the tumor site through intravenous injection. RFA destroys a
majority of the tumor site through thermal ablation, while the heat causes release of doxurubicin,
killing any remaining cancer cells.
Xyotax, CT-2103. OPAXIO was designed to deliver paclitaxel preferentially to tumor tissue. By
linking paclitaxel to a biodegradable amino acid carrier, the conjugated chemotherapeutic agent is
inactive in the bloodstream, sparing normal tissues the toxic side effects of chemotherapy. Once
inside tumor tissue the conjugated chemotherapeutic agent is activated and released by the action
of an enzyme called cathepsin B. The activity of this enzyme and thus the rate of release of paclitaxel
poliglumex is increased in the presence of estrogen.
Pegylated colloidal gold nanoparticles bound with TNF and paclitaxel.
hGH, a long-acting native human Growth Hormone for the treatment of growth disorders, and,
In Vivo
Biodegradable
IFN beta XL, a long-acting interferon beta for the treatment of multiple sclerosis.
In Vivo
Biodegradable
Radionuclides attached to perfluorocarbon nanoparticles.

Respiratory syncytial virus (RSV) vaccine based on the same virosome technology platform as Berna
Biotech. Administered intravenously. One of six virosome-based vaccines in clinical development for
Pevion Biotech Ltd.
Early phase development for delivery nanoparticles with variable size ranges.
In Vivo
Soft
In Vivo
Biodegradable
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Therapeutic
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
In Vivo Targeting
In Vivo
Use
Hard / Soft
Nanoparticle
92
Bexion, Qi, Chu
Confirmed
SapC-DOPS
Bexion Pharmaceuticals, Inc.
Biological
Solid Tumors
Saposin C
Liposome
190
Investigational
Preclinical

Foreign Country
Intravenous
Saposin C
In Vivo
Soft
93
Supratek
Confirmed
SP1060C-O
Supratek Pharma, Inc.
Drug
Solid Tumors
Topotecan
Micelle
10-100
Investigational
Preclinical
Oral
Passive
In Vivo
Soft
SP1060C-O is a proprietary orally bioavailable formulation of topotecan and a Biotransport carrier

that increases the bioavailability of the active (lactone) form of the drug. The product prototype is a
free flowing powder that is water-soluble and compressible into tablets.
94
Constantinides, Mersana
Confirmed
XMT-1107
Mersana Therapeutics
Drug
Solid Tumors
Fumagillin
Fleximer
5-10
Investigational
Preclinical
Intravenous
Passive
In Vivo
Soft
Fumagillin conjugated with Mersana's proprietary Fleximer technology. Fumagillin is an antiangiogenic agent. Fleximer is a biodegradable and bio-inert polymer that can be chemically linked to
small molecules, biologics and nucleic acids. Intravenously injected, intended for cancer treatment.
95
Dobrovolskaia
Confirmed
Basulin
Flamel Technologies
Drug
Type I Diabetes
Insulin
20-50
Terminated
Phase II
In Vivo
Biodegradable
Improved insulin delivery with the use of the proprietary Medusa nanoparticle system.
96
NCT00055133
Confirmed
Paxceed
Angiotech Pharmaceuticals
Drug
Solid Tumors
Paclitaxel
Micelle
<200
Terminated
Phase II
Intravenous
Passive
In Vivo
Soft
Micellar formulation of paclitaxel. Intravenously injected for arthritis treatment. Clinical

investigations were terminated due to lack of demonstrated efficacy.
97
NCT00096668, Constantinides
Confirmed
TOCOSOL
OncoGenex
Drug
Solid Tumors
Paclitaxel
Emulsion
40-80
Terminated
Phase II
Intravenous
Passive
In Vivo
Soft
Paclitaxel emulsion for intravenous injection. Anti-cancer chemotherapy agent for treatment of
various cancers. Terminated in Phase III because the new formulation was not able to demonstrate
increased efficacy over straight Taxol injections.
98
NCT00002742, Moribe
Confirmed
Nyotran
Aronex Pharmaceuticals, Inc
Drug
Solid Tumors
Nystatin
Liposome
110-135
Terminated
Phase III
In Vivo
Soft
Liposomal nystatin. Discontinued for unknown reasons.
99
Likely
Adagen
Enzon
Drug
Immunodeficiency
Pegademase Bovine
Approved
Mar-90
019818
Intramuscular
NA
In Vivo
Biodegradable
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the enzyme

adenosine deaminase (ADA). Enzyme is derived from bovine intestine. Intramuscular injection for
treatment of severe combined immunodeficiency disease (SCID).
100
Likely
Oncaspar-IV
Enzon
Drug
Leukemia
Pegaspargase
Approved
Feb-94
103411
Intravenous
Passive
In Vivo
Biodegradable
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the enzyme Lasparaginase. Enzyme is derived from E coli. Intravenous injection for treatment of leukemia.
101
Wagner, Project
Likely
Copaxone
TEVA
Drug
Multiple Sclerosis
Glatiramer Acetate
Approved
Dec-96
020622
Subcutaneous
NA
In Vivo
Biodegradable
Polymeric complex of glatiramer acetate (copolymer of L-glutamic acid, L-alanine, L-tyrosine, and Llysine). Subcutaneous injection to reduce the frequency of relapse with multiple sclerosis.
102
Faraji, Kanaoka
Likely
Ontak
Seragen, Inc.
Biological
Cutaneous T-cell lymphoma
Denileukin Diftitox
Protein Nanoparticle
Approved
Feb-99
103767
Intravenous
IL-2 Protein
In Vivo
Soft
103
Likely
DepoCyt
SkyePharma
Drug
Lymphomatous Meningitis
Cytarabine
Liposome
Approved
Apr-99
021041
Intravenous
Passive
In Vivo
Soft
104
Wagner, Bawa
Likely
Renagel
Genzyme
Drug
Chronic Kidney Disease
Sevelamer HCl
Approved
Jul-00
021179
Oral
NA
In Vivo
Biodegradable
105
Wagner, Bawa
Likely
Peg-Intron
Schering
Biological
Hepatisis C
Peginterferon Alpha-2B
Approved
Jan-01
103949
Subcutaneous
NA
In Vivo
Biodegradable
106
Likely
Neulasta
Amgen
Drug
Fibrile Neutopenia
Pegfilgrastim
Approved
Jan-02
125031
Subcutaneous
NA
In Vivo
Biodegradable
107
Likely
Pegasys
Enzon
Biological
Hepatisis C
Peginterferon Alpha-2A
Approved
Oct-02
103964
Subcutaneous
NA
In Vivo
Biodegradable
108
Wagner, Bawa
Likely
Somavert
Nektar Therapeutics
Drug
Acromegaly
Pegvisomant
Approved
Mar-03
021106
Subcutaneous
NA
In Vivo
Biodegradable
109
NCT00611403
Likely
RESTASIS
Allergan
Drug
Dry Eye Disease
Cyclosporine
Emulsion
Approved
Oct-03
021023
Topical
NA
In Vivo
Soft
110
Likely
Macugen
OSI Pharmaceuticals, Inc.
Drug
Macular Degeneration
Pegaptanib Sodium
Approved
Dec-04
021756
Intravenous
Passive
In Vivo
Biodegradable
111
TLC
Likely
Lipo-Dox
Drug
Solid Tumors
Doxorubicin
Liposome
Foreign Approval
2001
Taiwan
Intravenous
Passive
In Vivo
Soft
112
113
114
115
Emerich
Emerich, Nyman
Emerich
Emerich
Likely
Likely
Likely
Likely
Diazepam-Lipuro
Etomidate-Lipuro
Konakion MM
Valium MM
B. Braun Medical Inc.

B. Braun Medical Inc.
Roche
Roche
Drug
Drug
Drug
Drug
Tranquilizer
Anaesthetic
Nutrional Supplement
Tranquilizer
Diazepam
Etomidate
Phytomenadione
Diazepam
Emulsion
Emulsion
Micelle
Micelle
Foreign Approval
Foreign Approval
Foreign Approval
Foreign Approval
Intramuscular
Intravenous
Intramuscular
Intramuscular
NA
NA
NA
NA
In Vivo
In Vivo
In Vivo
In Vivo
Soft
Soft
Soft
Soft
National Cancer Institute
Other
Leukemia
Radioactive Actinium-225
Nanoparticle
Investigational
Phase I
Intravenous
HuM195 Antibody
In Vivo
Macromolecule
Interleukin 2-diptheria toxin fusion protein complex. Recombinant DNA-derived from E coli.
Intravenous injection for treatment of persistent or recurrent cutaneous T-cell lymphoma.
Liposomal cytarabine. Intravenously injected chemotherapy agent for treatment of lymphomatous
meningitis.
Poly (allylamine-co-N,N'-diallyl- 1,3-diamino-2-hydroxypropane) hydrochloride cross-linked drug
complex. Tablets are taken orally for controlling serum phosphorus in patients with chronic kidney
disease (CKD) on dialysis.
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the protein alfa-2b
interferon. Recombinant DNA-derived from Escherichia coli. Subcutaneous injection for treatment
of chronic hepatitis C.
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the protein
methionyl human G-CSF (Filgrastim). Recombinant DNA-derived from Escherichia coli.
Subcutaneous injection for treatment of febrile neutropenia (infection).
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the protein alfa-2a
interferon. Recombinant DNA-derived from Escherichia coli. Subcutaneous injection for treatment
of chronic hepatitis C.
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the protein
pegvisomant (analog of human growth hormone). Derived from Escherichia coli. Subcutaneous
injection for treatment of acromegaly.
0.05% cyclosporine ophthalmic emulsion. Topical administered anti-inflammatory for treatment of
dry eyes.
Monomethoxypolyethylene glycol (PEG) polymeric complex covalently bound to the oligonucleotide,
pegaptanib sodium. Intravitreous injection into the eye for treatment of neovascular (wet) agerelated macular degeneration.
Generic form of Doxil. TLC NanoX platform claims capability to produce liposomes in the 85-130nm
size range.
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal
Antibody HuM195). The antibody HuM195 will be used to deliver actinium-225 directly to leukemia
cells throughout the body. Once actinium-225 reaches these cells, it gives off four alpha particles,
killing the leukemia cells. Experiments show that actinium-225-HuM195 should be about 1,000
times more potent than bismuth-213-HuM195. Actinium-225-HuM195 was safe when it was given
to mice and monkeys. Structure is likely on the order of several nanometers based on the
description.
116
NCT00672165
Likely
ACTINIUM-225-LABELED HUMANIZED
ANTI-CD33 MONOCLONAL ANTIBODY
HuM195
117
NCT00664170, Zamboni
Likely
ANX-514
Adventrx Pharmaceuticals
Drug
Solid Tumors
Docetaxel
Emulsion
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
Docetaxel emulsion formulation. Docetaxel is a chemotherapy drug approved for treatment of

breast, non-small cell lung, prostate, gastric and head and neck cancers. Investigational
intravenous injection for treatment of various cancers.
118
NCT00004806
Likely
CFTR Gene Liposome
National Institute of Diabetes and Digestive

and Kidney Diseases (NIDDK)
Genetic
Cystic Fibrosis
CFTR Gene
Liposome
Investigational
Phase I
Nasal
NA
In Vivo
Soft
Liposome-mediated cystic fibrosis transport regulator (CFTR) gene transfer therapy for treatment of
cystic fibrosis. Administered to the nasal epithelium.
119
NCT01048008, Morgan
Likely
DM-CHOC-PEN
DEKK-TEC, Inc.
Drug
Brain Neoplasms
DM-CHOC-PEN
Emulsion
Investigational
Phase I
Intravenous
Penetrate
Blood-BrainBarrier
In Vivo
Soft
120
NCT00009841
Likely
Soft
NCT01278095
Likely
EGFR Antisense DNA And DC-Chol

Liposomes
GLPG0555
EGFR Antisense DNA And DC-Chol
121
122
NCT01556217
Likely
JNJ-39393406
123
Bissett, Matsumura (2007),

Schluep
Likely
124
Shah, NanoBio
125
Biological
Head and Neck Cancer
Liposome
Investigational
Phase I
Interstitial
Passive
In Vivo
Galapagos NV / GlaxoKlineSmith
Janssen Pharmaceutica NV / Johnson &
Johnson
Drug
Autoimmune Disorder
Nanosuspension
Investigational
Phase I
Oral
NA
In Vivo
Soft
4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) drug emulsion. Intravenous

injection for cancer treatment. Has demonstrated ability to cross the blood-brain barrier to target
localized cancers.
Liposome-mediated gene therapy for cancer treatment. Early stages of development and limited
information is available.
Drug
Schizophrenia
Nanosuspension
Investigational
Phase I
Oral
NA
In Vivo
Soft
MAG-CPT
Pharmacia & Upjohn Inc.
Drug
Solid Tumors
Camptothecin
Investigational
Phase I
Intravenous
Passive
In Vivo
Biodegradable
MAGCPT comprises the topoisomerase I inhibitor camptothecin linked to a water soluble polymeric
backbone methacryloylglycynamide (average molecular weight 18 kDa, 10% CPT by weight).
Likely
NanoStat
Nanobio Corporation
Biological
Molluscum Contagiosum
Vaccine
Emulsion
150-400
Investigational
Phase I
Topical
NA
In Vivo
Soft
Nanoemulsion droplets based on proprietary NanoStat technology. Antiviral formulations are under
clinical investigation. Treatment will be topically administered.
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Tinea Capitis
Vaccine
Emulsion
150-400
Investigational
Phase I
Topical
NA
In Vivo
Soft
126
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Influenza
Vaccine
Emulsion
150-400
Investigational
Phase I
Topical
NA
In Vivo
Soft
127
Shah, Pannu, NanoBio
Likely
NB-003
Nanobio Corporation
Drug
Acne
Antibiotic
Emulsion
150-400
Investigational
Phase I
Topical
NA
In Vivo
Soft
Nanoemulsion droplets based on proprietary NanoStat technology. Antibiotic drug formulations are
128
Nektar
Likely
NKTR-105
Nektar Therapeutics
Drug
Solid Tumors
Docetaxel
Investigational
Phase I
Intravenous
Passive
In Vivo
Biodegradable
129
NCT00004471
Likely
pGT-1 Gene Liposome
National Institute of Diabetes and Digestive

and Kidney Diseases (NIDDK)
Genetic
Cystic Fibrosis
pGT-1 Gene
Liposome
Investigational
Phase I
Nasal
NA
In Vivo
Soft
Liposome-mediated cystic fibrosis gene (pGT-1) gene transfer therapy for treatment of cystic
fibrosis. Administered to the nasal epithelium.
130
NCT01305512, Sun Pharma
Likely
PICN
Sun Pharma Advanced Research Company

Ltd.
Drug
Solid Tumors
Paclitaxel
Nanosuspension
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
131
Copernicus
Likely
PLASmin
Copernicus Therapeutics, Inc.
Genetic
Cystic Fibrosis
DNA
DNA NP
Investigational
Phase I
Aerosol
NA
In Vivo
Soft
Using compacted DNA (non-viral) to introduce normal copies of the gene into CF airways. A Phase
1a trial demonstrated chloride current changes in the noses of CF patients, but no evidence of gene
expression. The gene therapy product is being reformulated prior to additional clinical trials in an
attempt to improve the amount and duration of gene expression.
NKTR-105 is a novel form of the anti-mitotic agent, docetaxel, and was designed using Nektar's
advanced polymer conjugate technology. Expected to improve the pharmacokinetic profile of the
drug, resulting in prolonged exposure of the tumor to docetaxel and an improved timeconcentration profile.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Therapeutic
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase

Foreign Country
In Vivo Targeting
In Vivo
Use
Hard / Soft
Nanoparticle
132
Bawa
Likely
SGT-53
SynerGene Therapeutics, Inc.
Genetic
Solid Tumors
p53 Gene
Liposome
Investigational
Phase I
Intravenous
Transferrin
In Vivo
Soft
Liposome-mediated p53 gene transfer therapy for treatment of solid tumor cancers. p53 gene is a
vital tumor suppressor gene in humans. Delivered through intravenous infusion.
133
Tekmira
Likely
TKM-PLK1
Drug
Solid Tumors
siRNA
Liposome
Investigational
Phase I
Intravenous
Passive
In Vivo
Soft
Tekmira has taken advantage of this passive targeting effect to develop a LNP formulation directed
against PLK1 (polo-like kinase 1), a protein involved in tumour cell proliferation. Inhibition of PLK1
prevents the tumour cell from completing cell division, resulting in cell cycle arrest and cell death.
Uses same proprietary lipid nanoparticle (LNP) technology as TKM-ApoB platform.
134
NCT00952692
Likely
AS15
Biological
Metastatic Breast Cancer
dHER2
Liposome
Investigational
Phase I/II
Intravenous
dHER2 Antibody
In Vivo
Soft
The dHER2 + AS15 candidate Antigen-Specific Cancer Immunotherapeutic (ASCI) contains a

recombinant protein termed dHER2, which is a truncated version of the HER2 protein. HER2 is a
protein that is commonly overexpressed in breast cancer. This protein is combined with the
immunological adjuvant AS15 Adjuvant System from GSK (GlaxoSmithKline), which is a liposomal
formulation containing three immunostimulatory components.
135
Alexis, Soepenberg
Likely
DE-310
Daiichi Pharmaceutical Co. Ltd
Drug
Solid Tumors
Camptothecin
Investigational
Phase I/II
Intravenous
Passive
In Vivo
Biodegradable
136
NCT00005969, Manconi
Likely
Atragen
Aronex Pharmaceuticals, Inc
Drug
Solid Tumors
Tretinoin
Liposome
Investigational
Phase II
Intravenous
Passive
In Vivo
Soft
137
Matsumura (2007)
Likely
CT-2106
Cell Therapeutics, Inc.
Drug
Colorectal Cancer
Camptothecin
Investigational
Phase II
Intravenous
Passive
In Vivo
Biodegradable
CT-2106, a camptothecin (CPT) conjugate, is a new generation of topoisomerase I inhibitors

designed to deliver higher, more effective chemotherapy to tumor tissue with less toxicity to normal
tissues.
138
NCT00004104
Likely
IL-2 LIPO
Biological
Melanoma
Interleukin-2
Liposome
Investigational
Phase II
Subcutaneous
Passive
In Vivo
Soft
Liposomal formulation of Interleukin-2 for treatment of cancers. Phase II study was terminated for
treatment of solid tumors, but Phase II study is progressing for skin melanoma.
139
Shah, Pannu, NanoBio
Likely
NB-002
Nanobio Corporation
Drug
Onychomycosis
Antibiotic
Emulsion
Investigational
Phase II
Topical
NA
In Vivo
Soft
Nanoemulsion droplets based on proprietary NanoStat technology. Antibiotic drug formulations are
140
Nektar
Likely
NKTR-102
Nektar Therapeutics
Drug
Solid Tumors
Irinotecan
Investigational
Phase II
Intravenous
Passive
In Vivo
Biodegradable
NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile

that provides a continuous concentration of active drug with reduced peak concentrations. Polymer
conjugate technology platform and is the first oncology product candidate to leverage Nektar's
releasable polymer technology platform.
141
NCT00533637, Orexo
Likely
OX-NLA
Orexo AB
Drug
Allergic Rhinitis
Cetirizine HCl
Liposome
Investigational
Phase II
Nasal
NA
In Vivo
Soft
142
Debbage, Khemtong
Likely
PEG-SN38
Enzon
Drug
Metastatic Breast Cancer
Camptothecin
Investigational
Phase II
Intravenous
Passive
In Vivo
Biodegradable
143
Alexis, Izzo
Likely
ADI-SS PEG
Pheonix Pharmacologics, Inc.
Drug
Unresectable Hepatocellular Carcinoma
Arginine Deaminase
Investigational
Phase III
Intravenous
Passive
In Vivo
Biodegradable
144
TLC
Likely
AmBiL
Drug
Fungal Infections
Amphotericin B
Liposome
Investigational
Phase III
Intravenous
Passive
In Vivo
Soft
145
NCT00175877
Likely
CDP870 (Certolizumab Pegol)
UCB, Inc.
Biological
Crohn's Disease
Monoclonal Antibody
Investigational
Phase III
Subcutaneous
NA
In Vivo
Biodegradable
146
TLC
Likely
Doxisome
Drug
Solid Tumors
Doxorubicin
Liposome
Investigational
Phase III
ANDA
Intravenous
Passive
In Vivo
Soft
147
148
TLC
NCT00814515
Likely
Likely
ProFlow
Vekacia

Novagali Pharma
Drug
Drug

Dry Eye Disease
Palmitate Alprostadil
Cyclosporine
Emulsion
Emulsion
Investigational
Investigational
Phase III
Phase III
ANDA
Intravenous
Opthalmic
Passive
NA
In Vivo
In Vivo
Soft
Soft
149
Cerulean Pharma
Likely
CRLX228
Cerulean Pharma, Inc.
Drug
Solid Tumors
Investigational
Preclinical
Intravenous
Passive
In Vivo
Biodegradable
150
Sun Pharma
Likely
DICN
Sun Pharma Advanced Research Company

Ltd.
Drug
Solid Tumors
Docetaxel
Nanosuspension
Investigational
Preclinical
Intravenous
Passive
In Vivo
Soft
151
Mebiopharm
Likely
MBP-Y003
Mebiopharm Co., Ltd
Drug
Lymphoma
Methotrexate
Liposome
Investigational
Preclinical
Intravenous
Transferrin
In Vivo
Soft
MBP-Y003 is a transferrin-conjugated nano particle formulation of methotrexate(MTX) for the

indication of Lymphoma and other cancers. Has potential antitumor activity against various tumor
cell lines such as prostate cancers and lymphomas.
152
Mebiopharm
Likely
MBP-Y004
Mebiopharm Co., Ltd
Drug
Solid Tumors
Docetaxel
Liposome
Investigational
Preclinical
Intravenous
Transferrin
In Vivo
Soft
153
Mebiopharm
Likely
MBP-Y005
Mebiopharm Co., Ltd
Drug
Solid Tumors
Gemsitabine
Liposome
Investigational
Preclinical
Intravenous
Transferrin
In Vivo
Soft
154
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Hepatitis B
Vaccine
Emulsion
150-400
Investigational
Preclinical
Topical
NA
In Vivo
Soft
preclinical investigation. Treatment will be topically administered.
155
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Anthrax
Vaccine
Emulsion
150-400
Investigational
Preclinical
Topical
NA
In Vivo
Soft
156
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Anthrax/Plague/Botulinum
Vaccine
Emulsion
150-400
Investigational
Preclinical
Topical
NA
In Vivo
Soft
157
Shah, NanoBio
Likely
NanoStat
Nanobio Corporation
Biological
Small Pox
Vaccine
Emulsion
150-400
Investigational
Preclinical
Topical
NA
In Vivo
Soft
158
Tekmira
Likely
TKM-Ebola
Drug
Ebola
siRNA
Liposome
Investigational
Preclinical
Intravenous
NA
In Vivo
Soft
Novel anti-viral drug in the treatment of Ebola infection. Tekmira conducted a series of studies
demonstrating the ability of an RNAi therapeutic utilizing Tekmiras lipid nanoparticle (LNP)
technology to protect nonhuman primates from Ebola virus. Uses same proprietary lipid
nanoparticle (LNP) technology as TKM-ApoB platform.
Intravenous
Passive
150-400
159
Alexis, Danhauser-Riedl
Likely
AD-70
Alpha Therapeutic GmbH
Drug
Solid Tumors
Doxorubicin
Terminated
Phase I
160
Zamboni
Likely
CNF1010
Biogen Idec
Drug
Chronic Lymphocytic Leukemia
17-AAG
Emulsion
Terminated
Phase I
161
162
Alexis, Terwogt
Debbage, Satchi-Fainaro
Likely
Likely
PNU 166945
Caplostatin (TNP-470)
Pharmacia & Upjohn

Children's Medical Center Corporation
Drug
Drug
Cancer
Solid Tumors
Paclitaxel
TNP-470
Terminated
Terminated
Phase I
Phase II
163
Wagner, BioWorldToday
Likely
Propofol IDD-D
SkyePharma
Drug
Anesthetic
Propofol
Terminated
164
Roszek
Likely
Avidimer
Avidimer Therapeutics, Inc. (was NanoCure)
Drug
Solid Tumors
Methotrexate
Dendrimer
165
NCT00666328
Potential
Cleviprex
The Medicines Company
Drug
Cardiac Hypertension
Clevidipine Butyrate
166
Eurand
Potential
Mesulid Fast
Torrinomedica
Drug
Pain Relief
Nimesulide
167
Eurand
Potential
Biorise
Eurand
Drug
Nanocrystal
Foreign Approval
168
Shah
Potential
Ropion
Kaken Pharmeceuticals
Drug
Pain Relief
Fluriprofen Axetil
Emulsion
Foreign Approval
169
Acusphere
Potential
Al-850
Acusphere, Inc.
Drug
Solid Tumors
Paclitaxel
Nanoporous Material
Investigational
ANDA
In Vivo
Biodegradable
In Vivo
Soft
In Vivo
In Vivo
Biodegradable
Biodegradable
Phase III
In Vivo
Biodegradable
Terminated
Preclinical
In Vivo
Soft
Emulsion
Approved
Aug-08
Nanocrystal
Foreign Approval
Intravenous
Subcutaneous
Passive
NA
022156
Intravenous
NA
In Vivo
Italy
Oral
NA
In Vivo
In Vivo
Phase I
Intravenous
NA
In Vivo
Intravenous
NA
In Vivo
In Vivo
170
NCT00000847
Potential
ALVAC-HIV MN120TMG (vCP205)
National Institute of Allergy and Infectious

Diseases (NIAID)
Biological
HIV
Emulsion
Investigational
Phase I
Multiple
NA
171
NCT00432562
Potential
ANX-530
Adventrx Pharmaceuticals
Drug
Solid Tumors
Vinorelbine Tartrate
Emulsion
Investigational
Phase I
Intravenous
Passive
In Vivo
172
173
NCT01159028
NCT01095848
Potential
Potential
BP-100-1.01
DPX-0907
Bio-Path Holdings, Inc.

ImmunoVaccine Technologies, Inc.
Drug
Biological
Leukemia
Neoplasms
Grb-2
Cancer Vaccine
Liposome
Liposome
Investigational
Investigational
Phase I
Phase I
Intravenous
Subcutaneous
NA
NA
In Vivo
In Vivo
174
NCT00912574
Potential
GM-CSF Vaccine Emulsion
University of Virginia
Drug
Melanoma
Cancer Vaccine
Emulsion
Investigational
Phase I
Intravenous
Passive
In Vivo

Liposomal formulation of all-trans retinoic acidATRA for acute promyelocytic leukemia and other
hematologic malignancies, solid tumors. Intravenous injection. 2006 study indicates liposomal
tretinoin synthesis with average size capabilities ranging from 87 to 393 nm.
Liposomal formulation of cetirizine hydrochloride for treatment of hay fever. Administered through
a nasal spray.
(Pegamotecan, PEG-camptothecin, Prothecan) Liposomal formulation of comptothecin. Studies
have been terminated for unlisted reasons, but development has continued under various brand
and investigational names.
Structure has a molecular weight of 20,000.
First generic form of AmBisome. TLC NanoX platform claims capability to produce liposomes in the
85-130nm size range.
Engineered Human Anti-TNF PEG Conjugate.
Generic form of Doxil. TLC NanoX platform claims capability to produce liposomes in the 85-130nm
size range.
Generic form of Liple. Bioequivalency to Liple would require similar emulsion sizes.
Cyclosporine A opthalmic emulsion formulation for treatment of eye allergies.
RLX228, Ceruleans preclinical lead candidate from the PNP technology contains a widely used
oncology drug and is presently progressing into IND enabling studies. CRLX288 shows substantial
efficacy and safety improvement over parent drug in validated pre-clinical models and offers the
potential to dramatically improve the therapeutic index of the parent drug.
MBP-Y004 is a transferrin-conjugated nano particle formulation of Docetaxel, used for ovarian,

breast and non-small cell lung cancer.
MBP-Y005 is a transferrin-conjugated nano particle formulation of Gemsitabine, which is a
nucleoside used for cancer treatment such as non-small cell lung cancer, pancreatic cancer and
biliary cancer.
Dextran-conjugated doxorubicin. Discontinued due to severe hepatotoxicity.

Drug emulsion formulation for leukemia treatment. Study was terminated, but no indications are
listed as to why the program was terminated.
Discontinued due to severe neurotoxicity.
Propofol polymeric nanoparticle complex for anesthetic delivery. Study was terminated, but no
indications are listed as to why the program was terminated.
Avidimer Therapeutics develops and commercializes pharmaceuticals, called avidimers, based on
proprietary nanotechnology. Avidimers are "smart drugs, designed to maximize damage to disease
targets while minimizing collateral damage to healthy tissue." No recent information available.
Clevidipine butyrate emulsion formulation. Intravenous injection for rapidly reducing and
maintaining blood pressure.
Utilizes Biorise system (see below).
New Physical Entities (NPEs) are produced by breaking down the crystalline drug into nanocrystals
and/or amorphous (noncrystalline) drug that is stabilized in a carrier system to maintain the drug in
its activated form for the duration of its shelf life.
Fluriprofen axetil emulsion for pain relief. Intravenous injection.
Putting nanoparticles of paclitaxel into our sponge-like microspheres, creates a paclitaxel
formulation that is free of Cremophor and consists of paclitaxel nanoparticles in a porous,
hydrophilic matrix, composed primarily of a sugar that has been proven to be innocuous in other
injectable drugs.
Recombinant canarypox vaccine emulsion for HIV treatment. Investigating intramuscular,
intranasal, and intravaginal administration routes.
Vinorelbine tartrate emulsion formulation. Intravenous injection for treatment of various forms of
cancer.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) emulsion. GM-CSF encourages white
blood cell development. Intravenous injection for combination treatment of various forms of
cancer.
ID
References
Nanomedicine
Relevance
175
NCT00117429
Potential
176
NCT00001512
177
NCT00000847
178
Product Name or ID
FDA Classification
HIV gp120/NefTat/AS02A Vaccine
Potential
Id-KLH
Potential
Unknown
NCT00035867
Potential
Telintra
179
NCT00709254, YMBioSciences
Potential
AeroLEF
YM BioSciences
Drug
180
181
182
NCT00484120
NCT00915187
NCT01066988
Potential
Potential
Potential
Cannabinor
VaxiSome
ORB Ocular Emulsion
Pharmos Corporation.
NasVax Ltd
Alcon Research
Drug
Biological
Drug
183
NCT00143611
Potential
TAK-242
Takeda Global Research & Development

Center, Inc.
Drug
Sepsis
184
185
186
NCT00688519
Bio-Path
Bio-Path
Potential
Potential
Potential
U0267
BP-100-1.02
BP-100-2.01
Drug
Drug
Drug
Plaque Psoriasis
Lymphoma
Ovarian Cancer
187
NCT00059657
Potential
Circulase
Drug
188
Bawa
Questionable
Verelan
Elan Corporation
Drug
189
Questionable
Abelcet
Enzon
Drug
190
Bawa
Questionable
Naprelan
STAT TRADE
Drug
191
Bawa
Questionable
Verelan PM
Elan Corporation
192
Wagner, Project
Questionable
Rapamune
Wyeth
193
Bawa
Questionable
Avinza
194
Bawa
Questionable
Ritalin LA
195
Wagner, Project, Bawa
Questionable
Emend
Merck & Co., Inc.
196
Wagner, Project, Bawa, Bandak
Questionable
Estrasorb
Novavax
197
Questionable
TriCor
198
Bawa
Questionable
Focalin XR
199
Wagner, Bawa
Questionable
Triglide
SkyePharma
Drug
200
Questionable
Megace ES
Par Pharmaceutical Companies, Inc. (USA)
Drug
201
Bawa, Chu
Questionable
Elestrin
Biosante Pharmaceuticals
Drug
Menopausal Symptoms
202
Wagner
Questionable
Invega Sustenna
Johnson & Johnson
Drug
Schizophrenia
Therapeutic
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase

Foreign Country
In Vivo Targeting
In Vivo
Use
Intramuscular
NA
In Vivo
Intravenous
Idiotype Determinants
In Vivo
Hard / Soft
Nanoparticle

HIV gp120/NefTat/AS02A vaccine emulsion. Three recombinant HIV clade B viral antigens: the
envelope glycoprotein gp120 and two regulatory proteins, Nef and Tat.The antigens are formulated
in a proprietary adjuvant, AS02A, comprised of two immunostimulants in an oil-in-water emulsion
(produced by GlaxoSmithKline). Intramuscular injection.
Biological
HIV
gp120/NefTat/AS02A
Emulsion
Investigational
Phase I
Biological
Lymphoma
Id-KLH Vaccine
Emulsion
Investigational
Phase I
Biocine
Biological
HIV
Emulsion
Investigational
Phase I
Telik, Inc.
Drug
Myelodysplastic Syndromes
TLK199 HCl
Liposome
Investigational
Phase I/II
Pain Relief
Fentanyl
Liposome
Investigational
Phase II
Aerosol
NA
In Vivo
Osteoarthritis
Influenza
Sjogren's Syndrome
CB2 Antagonist
Vaccine
Emulsion
Liposome
Emulsion
Investigational
Investigational
Investigational
Phase II
Phase II
Phase III
Intravenous
Intramuscular
Opthalmic
Passive
NA
NA
In Vivo
In Vivo
In Vivo
TLR4
Emulsion
Investigational
Phase III
Subcutaneous
NA
In Vivo
Calcipotriene
Bcl-2
siRNA
Emulsion
Liposome
Liposome
Investigational
Investigational
Investigational
Phase III
Preclinical
Preclinical
Topical
Intravenous
Intravenous
NA
NA
NA
In Vivo
In Vivo
In Vivo
Ecraprost
Emulsion
Terminated
Phase III
Intravenous
Passive
In Vivo
Ecrapost emulsion formulation for treatment of severe peripheral vascular disease (PVD). Study
was terminated, but no indications are listed as to why the program was terminated.
Hypertension
Verapamil Hydrochloride
NanoCrystal Dispersion
<2000
Approved
May-90
019614
Oral
NA
In Vivo
Elan's NanoCrystal Technology drug formulation. Wet-milled to particle sizes <2000nm. Surfacecoated to prevent agglomeration.
Fungal Infections
Amphotericn B
Liposome
1600-11000
Approved
Nov-95
050724
Intravenous
NA
In Vivo
Anti-Inflammatory
Naproxen Sodium
<2000
Approved
Jan-96
020353
Oral
NA
In Vivo
Drug
Hypertension
Verapamil Hydrochloride
<2000
Approved
Nov-98
020943
Oral
NA
In Vivo
Drug
Immunosuppressant
Sirolimus
<2000
Approved
Sep-99
021083
Oral
NA
In Vivo
King Pharmeceuticals
Drug
Chronic Pain
Morphine Sulfate
<2000
Approved
Mar-02
021260
Oral
NA
In Vivo
Drug
ADHD
Methylphenidate Hydrochloride
<2000
Approved
Jun-02
021284
Oral
NA
In Vivo
Drug
Anti-Nausea
FOSAPREPITANT DIMEGLUMINE
<2000
Approved
Mar-03
021549
Oral
NA
In Vivo
Drug
"Hot Flashes"
Estradiol Hemihydrate
Emulsion
10-1000
Approved
Oct-03
021371
Topical
NA
In Vivo
Abbott Laboratories
Drug
Cholesterol
Fenofibrate
<2000
Approved
Nov-04
021656
Oral
NA
In Vivo
Drug
ADHD
Dexmethylphenidate Hydrochloride
<2000
Approved
May-05
021802
Oral
NA
In Vivo
Lipid Regulation
Fenofibrate
<2000
Approved
May-05
021350
Oral
NA
In Vivo
Appetite Stimulant
Megestrol Acetate
<2000
Approved
Jul-05
021778
Oral
NA
In Vivo
Estradiol
Nanoparticle
70-1000
Approved
Dec-06
021813
Topical
NA
In Vivo
Paliperidone Palmitate
<2000
Approved
Jul-09
022264
Intramuscular
NA
In Vivo
In Vivo
Terminated?
In Vivo
Oral
NA
In Vivo
203
Bandak
Questionable
Androsorb
Novavax
Drug
Testosterone
Emulsion
10-1000
Approved
Inactive
052065
Topical
NA
204
Bawa
Questionable
Theo-Dur
Key Pharmaceuticals
Drug
Asthma
Theophylline
<2000
Discontinued
Jan-84
089131
Oral
NA
In Vivo
205
Bawa
Questionable
Herbesser
Tanabe Seiyaku Co., Ltd.
Drug
Angina
Diltiazem HCl
<2000
Foreign Approval
1974
Japan / Asia
Oral
NA
In Vivo
In Vivo
Id-KLH vaccine emulsion for treatment of lymphoma.

Clinical trial for HIV vaccine emulsion, but detailed information was not provided. Study may have
been terminated.
Liposomal ezatiostat hydrochloride (TLK199) for treatment of myelodysplastic syndrome (MDS).
Inhibits the enzyme, glutathione S-transferase P1-1. GSTP1-1 is a key regulatory protein that can
signal the cell to either make more blood elements or if the cell is cancerous to die. Oral tablet.
Proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in
development for the treatment of moderate to severe acute pain.
Synthetic CB2-selective agonist emulsion for pain relief. Intravenous injection.
Liposomal adjuvant for influenza vaccine. Intramuscular injection.
Ocular emulsion for treatment of dry eyes.
TAK-242 emulsion for treatment of severe sepsis. TAK-242 is a small molecule suppressor of
pathogen-induced release of inflammatory cytokines and acts by inhibiting TLR-4 mediated
signaling. Subcutaneous injection.
Vaccine emulsion for treatment of skin disease. Topically administered.
Liposomal formulation of amphotericin B for treating fungal infections. Intravenous injection.

Estradiol hemihydrate micellar emulsion for treatment of hot flashes. Transdermal application.
Estradiol gel (0.06%) incorporating calcium phosphate nanoparticles. Transdermal delivery.
Testosterone micellar emulsion. Transdermal application. Product is approved, but does not list any
treated conditions and is not currently an active product.
Liposomal formulation of glucantime for treatment of skin infections (Leishmaniasis). Administered
topically.
Liposomal formulation of meglumine antimoniate for treatment of skin infections (Leishmaniasis).
Administered topically.
Biodegradable calcium phosphate (CaP), protein complex nanoparticles. Application as drug delivery
platform.
Biodegradable calcium phosphate (CaP), protein complex nanoparticles. Application as drug delivery
platform.
Biodegradable calcium phosphate (CaP), protein complex nanoparticles. Application as vaccine
adjuvant.
206
NCT01050777
Questionable
Liposomal Glucantime
Tehran University of Medical Sciences
Drug
Cutaneous Leishmaniasis
Glucantime
Liposome
400
Investigational
Phase 0
Topical
NA
207
NCT01050777, Schettini
Questionable
Liposomal Meglumine Antimoniate
Instituto de Ciencias Biologicas
Drug
Cutaneous Leishmaniasis
Meglumine Antimoniate
Liposome
400
Investigational
Phase 0
Topical
NA
In Vivo
208
Chu, BioSantePharma
Questionable
BioAir
Drug
Protein Adjuvant
Protein
Nanoparticle
70-1000
Investigational
Phase I
Inhalation
NA
In Vivo
209
Chu, BioSantePharma
Questionable
BioOral
Drug
Protein Adjuvant
Protein
Nanoparticle
70-1000
Investigational
Phase I
Oral
NA
In Vivo
210
Chu, BioSantePharma
Questionable
BioVant
Biological
Vaccine Adjuvant
Vaccine
Nanoparticle
70-1000
Investigational
Phase I
Intramuscular
NA
In Vivo
211
NCT00922363, Christensen
Questionable
CAF01
Statens Serum Institut
Biological
Tuberculosis
Vaccine
Liposome
450
Investigational
Phase I
Intramuscular
NA
In Vivo
Cationic liposomal adjuvant used for tuberculosis vaccine delivery. Intramuscular injection.
212
NCT00968604, Xie
Questionable
C-VISA BikDD
Genetic
Pancreatic Cancer
BikDD
Liposome
405
Investigational
Phase I
Intravenous
VISA
In Vivo
C-VISA BikDD: liposome consists of a pancreatic-cancer-specific expression vector VISA (VP16GAL4-WPRE integrated systemic amplifier) and a pancreatic-cancer-specific promoter CCKAR
(cholecystokinin type A receptor) (CCKAR-VISA or C-VISA) which drives expression of the gene
BikDD. Intravenous injection for cancer treatment.
213
Bawa, NCT00059605, Ito
Questionable
INGN-401
Introgen Therapeutics, Inc.
Genetic
Lung Cancer
DOTAP:Chol-fus1
Liposome
375
Investigational
Phase I
Intravenous
Passive
In Vivo
Liposomal cholersterol FUS1 gene complex for treatment of lung cancer. Intravenous injection.
Experimental gene transfer. It is thought that the absence of the fus1 gene may be involved in the
development of lung cancer tumors.
214
NCT00024648, Rudin
Questionable
LE-rafAON
NeoPharm, Inc.
Drug
Neoplasms
LErafAON-ETU
Liposome
400
Investigational
Phase I
Intravenous
Passive
In Vivo
"Easy-to-use" liposomal formulation of an antisense oligonucleotide (AON) complementary to the craf mRNA sequence, which mediates tumor cell growth. This drug formulation utilizes the
Company's NeoPhectin(TM) transfection reagent which consists of a novel, positively charged,
synthetic cardiolipin (PCL-2). Intravenous injection.
215
NanoCyte
Questionable
NanoCyte
NanoCyte
216
NCT01073371, Saia Cereda
Questionable
PLCLUV
217
NCT00775138, Li
Questionable
Arikace
Transave
218
NCT00764361, Yu
Questionable
NanoDOX
219
NCT00400348
Questionable
220
NCT00157209, Elamanchili
Questionable
221
Capsulation, Roszek
Questionable
222
NCT00816829
Questionable
Phase I
Subcutaneous
NA
In Vivo
NanoCyte is leveraging a sophisticated natural injection system that evolved in sea life over the last
700 million years. The NanoCyte micro-injectors are harvested from sea-anemones, which are
cultivated in a closed, circulatory system at our facilities. The micro-injectors are composed of a
collagen-based capsule with an internal coiled microscopic nano-needle. Upon combination with the
active solution (drug or cosmeceutical), a high pressure of 150 atmospheres is developed within the
micro-injector, resulting in an unfolding of the long thin nano-needle out of the microcapsule at an
extremely high speed. During the penetration process, the active solution is pumped into, and
through the micro-injector, into the skin.
Investigational
Phase I
Interstitial
NA
In Vivo
Prilocaine-lidocaine cream liposomal unilaminar vesicle (PLCLUV). Interstitial injection.
Investigational
Phase I/II
Aerosol
NA
In Vivo
Sustained-release liposomal formulation of amikacin for treatment of lung infections. Dosage is

inhaled.
Investigational
Phase II
Topical
NA
In Vivo
1% doxycycline monohydrate hydrogel is a topical gel that is intended for direct contact with the
wound and is applied to the entire surface of the wound bed. A secondary dressing, such as gauze
or non-adhering dressing, is applied to cover. Anti-inflammatory to facilitate wound healing.
<2000
Investigational
Phase II
Oral
NA
In Vivo
Liposome
150-580
Investigational
Phase II/III
Intravenous
NA
In Vivo
Liposomal cancer vaccine designed to induce an immune response to cancer cells that express
MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many
cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer.
Investigational
Preclinical
Nanocrystal Dispersion
<2000
Terminated
Phase II
Oral
NA
Drug
Lidocaine
Nanoneedle
Investigational
Drug
Dental Anesthesia
Prilocaine
Liposome
400
Drug
Cystic Fibrosis
Amikacin
Liposome
375
Nanotherapeutics, Inc.
Drug
Foot Ulcer, Diabetic
Doxycycline Monohydrate
Liposome
200-350
Panzem Nanocrystal Colloidal Dispersion

(NCD)
EntreMed
Drug
Solid Tumors
2-Methoxyestradiol
Nanocrystal Dispersion
Stimuvax
Oncothyreon
Biological
Solid Tumors
BLP25 Vaccine
Nanocapsules
Capsulation
Drug
Fenobibrate Nanocrystal Colloidal

Dispersion (NCD)
Abbott Laboratories
Drug
Sleep Apnea
Fenofibrate
In Vivo
In Vivo
Capsule walls are generally comprised of 4 to 20 layers with a thickness of 8 - 50nm. Scaling would
suggest a total size on the order of microns.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Therapeutic
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase

Foreign Country
In Vivo Targeting
In Vivo
Use
Hard / Soft
Nanoparticle

Proprietary hydrogel polymer system, the vaginal insert is a sustained-release formulation of
dinoprostone, a synthetic prostaglandin E2 used when there is a medical need for cervical ripening,
i.e., preparing the cervix for labor.
Desonide hydrogel gel for the treatment of mild to moderate atopic dermatitis. Topically
administered.
223
NCT00308711
Unlikely
Cervidil/Propess
Cytokine PharmaSciences, Inc.
Drug
Pregnancy
Dinoprostone
Hydrogel
Approved
Mar-95
020411
Vaginal
NA
In Vivo
224
NCT00690833
Unlikely
Desonate
INTENDIS
Drug
Atopic Dermatitis
Desonide
Hydrogel
Approved
Oct-06
021844
Topical
NA
In Vivo
225
BioDelivery, Santangelo
Unlikely
Bioral
BioDelivery Sciences International, Inc.
Drug
Fungal Infections
Amphotericin B
Nanocochleate
Investigational
Phase I
Oral
NA
In Vivo
Bioral is a novel drug delivery system, based upon cochleate technology. Bioral encapsulates and
protects a drug without chemically bonding to it and may facilitate oral dosing of drugs that typically
need to be given by intravenous administration. Alternating layers of lipids spiral around a drug
molecule, encapsulating it and potentially protecting it from degradation by acid or digestive
enzymes in the stomach.
Investigational
Phase I
Implant
NA
In Vivo
Investigational
Phase I
Intravenous
NA
In Vivo
Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) for treatment of nonmetastatic osteosarcoma in children. Intravenous injection. Formerly known as known as Junovan.
407
226
NCT00981006
Unlikely
Implanted Hydrogel Drug Release
Japan National Cardiovascular Center
Biological
Congestive Heart Failure
bFGF
Hydrogel
227
NCT00631631, Jain
Unlikely
L-MTP-PE
Millennium Pharmaceuticals, Inc.
Drug
Osteosarcoma
L-MTP-PE
Liposome
228
Rainbow
Unlikely
Thymectacin
Newbiotics, Inc.
Drug
Colorectal Cancer
Brivudine Phosphoramidate
Investigational
Phase I/II
Intravenous
NA
In Vivo
The particle appears to be microscale based on the descriptions.
229
NCT01051258
Unlikely
AeriSeal
Aeris Therapeutics
Biological
Pulmonary Emphysema
BLVR
Hydrogel
Investigational
Phase II
Aerosol
NA
In Vivo
Physician uses a bronchoscope to direct treatment to the most damaged areas of the patients
lungs. Using a catheter, the proprietary hydrogel sealant is administered to the small airways and
alveoli at the treatment site. The foam sealant is delivered as a liquid and polymerizes in situ to form
a soft, elastic, adhesive foam.
230
NCT01247818
Unlikely
PH-10
Provectus Pharmaceuticals
Drug
Plaque Psoriasis
Rose Bengal Disodium
Hydrogel
Investigational
Phase II
Topical
NA
In Vivo
Topical rose bengal disodium hyrdogel gel for the treatment of psoriasis and other skin conditions.
231
NCT00828711
Unlikely
Misodel / Misopess
Cytokine PharmaSciences, Inc.
Drug
Labor Induction
Misoprostol
Hydrogel
Investigational
Phase III
Vaginal
NA
In Vivo
232
NCT00481884
Unlikely
RadiaPlexRx
MPM Medical, Inc.
Other
Radiation Dermatitis
Sodium Hyaluronate
Hydrogel
Investigational
Phase III
Topical
NA
In Vivo
710
Uses the same vaginal delivery system as Cervidil/Propess, but with a different active ingredient:
misoprostol.
Sodium hyaluronate hydrogel gel for treatment of radiation reactions, pressure ulcers, minor burns,
cuts and abrasions.
Table SM.2. Potential nanomedicine device products.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
FDA Application Number

or Foreign Country
In Vivo Targeting
In Vivo
Use
Soft / Hard
Nanoparticle
Active
Nanotechnology
Wagner, Wang, MR-TechIP,

Hayat
Confirmed
Feridex IV
Advanced Magnetics
Drug
In Vivo Imaging
SPIO
100-250
Approved
Aug-96
020416
Intravenous
Passive
In Vivo
Hard
Active

Hayat
Confirmed
Gastromark
Advanced Magnetics
Drug
In Vivo Imaging
SPIO
300
Approved
Dec-96
020410
Oral
Passive
In Vivo
Hard
Active

Hayat
Confirmed
Resovist
Schering
Drug
In Vivo Imaging
SPIO
60
Approved
Mar-01
Intravenous
Passive
In Vivo
Hard
Active
Wagner, Project, Wilson
Confirmed
CellTracks
Immunicon Corporation
Device
In Vitro Diagnostic
Nanoparticle
100
Approved
Nov-03
K030263
In Vitro
NA
In Vitro
Hard
Active
Wagner, Project
Confirmed
Vitoss
Orthovita
Device
Bone Substitute
Nanoscaffold
100
Approved
Dec-03
K032288
Implant
NA
In Vivo
Nanocrystal HA
NA
Project, Pagliaro
Confirmed
Neowater
Do-Coop Technologies Ltd.
Device
Micelle
5-50
Approved
Feb-04
Drug Master File
In Vivo
Soft
NA
Project
Confirmed
TiMESH
GfE Medizintechnik GmbH
Device
Tissue Engineering
Nanocoating
30
Approved
Mar-04
K031225
Implant
NA
In Vivo
Nanostructured
Material
NA
Wagner, Spies
Confirmed
Ostim
Osartis
Device
Bone Substitute
Nanocomposite
20
Approved
Dec-04
K030052
Implant
NA
In Vivo
Nanocrystal HA
NA
Confirmed
Acticoat
Smith & Nephew, Inc.
Device
Medical Dressing
Nanosilver
15
Approved
Apr-05
K050030
Wound Care
NA
Ex Vivo
Hard
NA
Confirmed
Ceram X Duo
Dentspley
Device
Dental Composite
Nanocomposite
2-10
Approved
Aug-05
K052097
Dental
NA
In Vivo
Hard
NA
10
Wagner, Project, Hayman,

Trop, Lu
Wagner, CeramX
11
Hayman
Confirmed
ON-Q SilverSoaker
I-Flow Corporation
Device
Device Coating
Nanosilver
10
Approved
Dec-05
K051401
Surgical
NA
In Vivo
Hard
NA
12
Project, AcryMed
Confirmed
SilvaGard
AcryMed, Inc.
Device
Device Coating
Nanosilver
10
Approved
Dec-05
K051401
Implant
NA
In Vivo
Hard
NA
13
Wagner, Filtek, Schmid
Confirmed
Filtek
3M Company
Device
Dental Composite
Nanocomposite
5-75
Approved
Dec-08
K083610
Dental
NA
In Vivo
Hard
NA
14
Bao
Confirmed
Technetium Tc 99m Colloids
Multiple
Drug
In Vivo Imaging
Nanocolloid
<30 nm
Approved
Multiple
Multiple
Intravenous
Passive
In Vivo
Molecular
NA
15
NCT00291603, Helixone
Confirmed
Fresenius Polysulfone Helixone
NephroCare
Device
Dialysis Filter
Nanoporous Material
3.3
Approved
Phase IV
K970700
In Vitro
NA
In Vitro
Nanostructured
Material
NA
16
NCT01062204, St. John
Confirmed
Altrazeal Dressing (Nanoflex Technology)
ULURU, Inc.
Device
Medical Dressing
Hydrogel
28-78
Commercial
Jun-08
Wound Care
NA
Ex Vivo
Soft
NA
17
Debiotech, Roszek
Confirmed
Nanosilver Healthcare Textiles
JR Nanotech PLC
Device
Healthcare Textile
Nanosilver
25-250
Commercial
External
NA
Ex Vivo
Hard
NA
18
Luebbe
Confirmed
Magnetic Drug Targeting
Pharmacia
Device
Drug Delivery
Nanoparticle
100
Discontinued
Phase I
Intravenous
Magnetic
In Vivo
Hard
Active
19
Spies
Confirmed
Biobon
Merck Biomaterial GmbH
Device
Bone Substitute
Nanocomposite
20-50
Foreign Approval
Nov-98
Implant
NA
In Vivo
Nanocrystal HA
NA
20
Wang, MR-TechIP, Hayat
Confirmed
Endorem
Guebert
Drug
In Vivo Imaging
SPIO
80-150
Foreign Approval
<2000
Intravenous
Passive
In Vivo
Hard
Active
32
Rivera Gil
Confirmed
NanoTherm
MagForce Nanotechnologies AG
Device
Solid Tumors
SPIO
10-15
Foreign Approval
Feb-11
European Union
Interstitial
Passive
In Vivo
Hard
Active
21
Wagner, Rauschmanna
Confirmed
Perossal
aap impantate
Device
Bone Substitute
Nanocomposite
17
Foreign Approval
2003
European Union
Implant
NA
In Vivo
Nanocrystal HA
NA
22
NCT00337714, Guggenbichler
Confirmed
LogiCath AgTive
Smiths Medical International
Device
Device Coating
Nanosilver
10
Foreign Approval
2006
Phase IV
Surgical
NA
In Vivo
Hard
NA
23
PlasmaChem
Confirmed
BioDiamond Stents
Device Coating
Nanocoating
Foreign Approval
Implant
NA
In Vivo
Nanostructured
Material
NA
PlasmaChem
Device
European Union

Superparamagnetic iron-oxide nanoparticles with dextran coating. Liverspecific contrast agent targeted through passive uptake. Prepared as
colloidal solution for intravenous injection.
Superparamagnetic iron-oxide nanoparticles with dextran coating. Bowelspecific contrast agent targeted through oral injestion and passage
through the gastrointestinal tract.
colloidal solution for intravenous injection.
Magnetic nanoparticles targeted to specific cell types with anitbodies.
Nanoparticles (and attached cells) are magnetically separated,
fluorescently marked, and imaged for detection.
Particles approximately 100 nm in size, making up highly porous, 3dimensional -TCP scaffolds with pores ranging from 1 to 1000 m in
size. Structure serves as implantable bone substitute.
Well-controlled micelles approved for drug-delivery applications. DoCoop has not yet partnered with anyone to produce an approved
pharmaceutic application.
Soft tissue reinforcement mesh implant. Excellent biocompatibility due
in part to a layer of titanium < 30 nm thick covalently bonded to the
surface.
Fully synthetic nanocrystalline hydroxyapatite paste which is injected
into a bone voids or defects. The fill resorbs and is replaced with bone
during the healing process.
Surgical dressing coated with silver nanocrystals, offering anti-microbial
and moisture control.
Nanoceramic dental composite.
Silver nanoparticle, anti-microbial coated catheter. First and only
approved device utilizing the SilvaGard brand nanoparticle coating.
Silver nanoparticle, anti-microbial coatings for medical devices. The IFlow Corporation ON-Q SilverSoaker intravenous catheter was approved
for use with SilvaGard in 2005, but no other devices have used the
SilvaGard coating.
Dental composite consisting of silica nanoparticles (75nm) with
zirconium nanoparticles (5-20nm).
Radioactive colloid used in scintillation scanning of the
reticuloendothelial system (RES). Intravenous injection collects
preferentially in liver, spleen, and bone marrow, for imaging. Has been a
standard imaging protocol for many years and kits are available from
many manufacturers.
Kidney dialysis system with specialized nanoporous membrane.
Helixone membrane is manufactured using a process involving Nano
Controlled Spinning (NCS) technology. It is possible to create the inner
membrane layer with a defined pore structure and pore distribution
profile according to the desired application.
Hydrogel powder is applied to an exuding wound by sprinkling the on
the open wound. The particles then hydrate and aggregate, becoming a
moist, flexible film over the surface of the open wound that provides an
ideal moist wound environment for healing.
Healthcare textiles embedded with nanosilver particles.
External magnetic fields were used to direct magnetic nanoparticles
conjugated to an anti-cancer drug, to the tumor site. It does not appear
the study progressed beyond Phase I, due to minimal increases in
efficacy.
Fully synthetic nanocomposite bone substitute paste which is injected
colloidal solution for intravenous injection. Foreign brand of Feridex
(discontinued in US).
Magnetically heated iron-oxide nanoparticles for tumor ablation.
Colloidal solution is injected directly into the treatment site. Treatment
requires use of a special magnetic field applicator.
Combines the biodegradable nanocomposite, Ostim (listed above), with
delivery of antibiotics to the bone repair site.
Central venous catheter with silver nanoparticle, antimicrobial coating to
prevent infections.
Uniform coating of the inner and outer stainless steel surface with
Diamond-Like Carbon by a specially developed Plasma-Induced Cold
Deposition Technique. The coating is ultra-thin (50 nm), extremely
sturdy, smooth and flexible.
Cutting edge is coated with a pure diamond film which is sharpened with
a plasma sharpening process that can form an almost atomically sharp
cutting edge. Transmission electron microscopy investigations have
shown that with the radius of curvature at the cutting edge can be as
small as 3nm.
24
Roszek
Confirmed
Diamaze
Gesellschaft fr Diamantprodukte mbH

(GFD)
Device
Surgical
Nanostructured Surface
Foreign Approval
Surgical
NA
In Vivo
Nanostructured
Material
NA
25
Confirmed
Lumirem
Guebert
Drug
In Vivo Imaging
SPIO
300
Foreign Approval
Oral
Passive
In Vivo
Hard
Active
through the gastrointestinal tract. Foregin brand of GastroMARK.
26
Bawa, Schwartz
Confirmed
AuroShell
Nanospectra Biosciences
Device
Solid Tumors
Nanoparticle
150
Investigational
Phase I
Intravenous
Passive
In Vivo
Hard
Active
Near infrared (NIR) laser excited gold nanoshells (with silica core) for
head and neck cancer tumor ablation. Systemic intravenous injection of
colloidal nanoparticle solution with passive, size-dependant targeting.
Once the nanoshells reach the tumor, they are excited (heated) with an
NIR laser. NIR radiation can penetrate tissue at shallow distances.
27
NCT00880802, Thaxton
Confirmed
nanoPSA
Nanosphere, Inc.
Device
In Vitro Diagnostic
Colloidal Gold
30
Investigational
Phase I
In Vitro
NA
In Vitro
Hard
NA
Colloidal gold nanoparticles used in in vitro testing.
28
NCT01206023, Peng
Confirmed
NA-NOSE
Israel Institute of Technology
Device
In Vitro Diagnostic
Investigational
Phase I
In Vitro
NA
In Vitro
Hard
NA
The discriminative power of a tailor-made Nanoscale Artificial Nose (NANOSE) based on an array of five gold nanoparticle sensors was tested.
The NA-NOSE signals were analysed to detect statistically significant
differences between sub-populations in clinical study.
29
Rivera Gil, Nanobiotix
Confirmed
nanoXRay
Nanobiotix
Device
Solid Tumors
Nanoparticle
70
Investigational
Phase I
In Vivo
Hard
Active
Nbtxr3 is a dense, biocompatible nanoparticle with an unknown coating,

designed to infiltrate only the targeted tumors cells. Once inside the
tumors cells, nbtxr3 nanoparticles have properties that convert
incoming, standard X-ray radiation into an efficient emission of electrons
responsible for the generation of free radicals.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
30
NCT00299598
Confirmed
Antibacterial Dental Composite
Hadassah Medical Organization
Device
Dental Composite
Nanoparticle
<100
Investigational
31
NCT01007240
Confirmed
Antibacterial Liner
Hadassah Medical Organization
Device
Healthcare Textile
Nanoparticle
<100
33
Confirmed
Combidex (Ferumoxtran-10)
Advanced Magnetics
Drug
In Vivo Imaging
SPIO
34
NCT00659204, Rai
Confirmed
SilvaSorb (SilvaGard)
AcryMed, Inc.
Device
Creams and Gels
35
Confirmed
Sinerem
Guebert
Drug
36
MR-TIP, Roszek, X. Zhang

(2001)
Confirmed
Supravist
Schering
Device
37
Blue Membrane
Confirmed
Blue Membrane Nano-Carbon Coatings
Blue Membranes GmbH
Device
In Vivo Targeting
In Vivo
Use
Soft / Hard
Nanoparticle
Active
Nanotechnology
Phase II
Dental
NA
In Vivo
Soft
NA
Antibacterial application of alkylated polyethylenimine nanoparticles

incorporated into flowable hybrid composite resin disks embedded in a
palatal removable appliance for dental restoration.
Investigational
Phase II
External
NA
Ex Vivo
Soft
NA
Anitbacterial application of crosslinked quaternary ammonium

polyethylenimine (PEI) nanoparticles incorporated at 1-2% w/w in a
commercial soft liner material.
20-40
Investigational
Phase III
Intravenous
Passive
In Vivo
Hard
Active
Nanosilver
2 to 20
Investigational
Phase III
External
NA
Ex Vivo
Hard
NA
In Vivo Imaging
SPIO
20-40
Investigational
Phase III
Intravenous
Passive
In Vivo
Hard
Active
In Vivo Imaging
SPIO
20
Investigational
Phase III
Intravenous
Passive
In Vivo
Hard
Active
In Vivo
Nanostructured
Material
NA
Device Coating
Nanoporous Material
38
Debiotech, Roszek
Confirmed
Debiostar
Debiotech SA
Device
Implantable Drug Delivery
Nanoporous Material
39
Kereos, Roszek, Schmieder
Confirmed
Ligand-Targeted Emulsion
Kereos, Inc.
Drug
In Vivo Imaging
Emulsion
40
Luna, Mraz, Roszek
Confirmed
TRIMETASPHERE
Luna Innovations, Inc.
Device
In Vivo Imaging
Fullerene
2.5+
50-80
270
0.8
Investigational

or Foreign Country
Preclinical
Implant
NA
Platypus
Confirmed
Implant
NA
In Vivo
Nanostructured
Material
NA
Investigational
Preclinical
Intravenous
Ligand
In Vivo
Soft
NA
Fibrin-targeted nanoparticles bound with gadolidium for enhanced MR

imaging contrast.
Investigational
Preclinical
55
Investigational
Quantum Dot
15-20
Research Use
Device
Qdot Nanocrystals
Invitrogen Corporation
Device
In Vitro Diagnostic
NA
In Vitro
NA
In Vitro
Nanostructured Material
NA
In Vitro
NA
In Vitro
Hard
Active
43
OceanNanotech
Confirmed
Affinity IOs
OceanNanotech, LLC.
Exempt
In Vitro Diagnostic
SPIO
10-30
Research Use
In Vitro
NA
In Vitro
Hard
NA
44
45
BBInternational
BBInternational
Confirmed
Confirmed
Bio-Conjugated Nanoparticles
Bio-Conjugated Nanoparticles
BBInternational
Nanoprobes, Inc.
Exempt
Exempt
In Vitro Diagnostic
In Vitro Diagnostic
Colloidal Gold
Colloidal Gold
2-250
1.8, 5, 10, 15
Research Use
Research Use
In Vitro
In Vitro
NA
NA
In Vitro
In Vitro
Hard
Hard
NA
NA
46
Miltenyi
Confirmed
FeraSpin
Exempt
In Vivo Imaging
SPIO
10-100
Research Use
In Vitro
NA
In Vitro
Hard
Active
Device
In Vitro Diagnostic
Nanoparticle
50-200
Research Use
In Vitro
NA
In Vitro
Hard
Active
Chemicell
Confirmed
fluidMAG-affinity
Nov-07
Hard
Project, Invitrogen, Qdot
Miltenyi Biotec
chemicell
Drug-eluting stent coatings.
Preclinical
In Vitro Diagnostic
Platypus Technologies
Silver nanoparticle antibacterial hand gel. Utilizes same silver

nanoparticle technology as SilvaGard medical device coatings.
Superparamagnetic iron-oxide nanoparticles with unknown coating. Can
assist in the differentiation of metastatic and non-metastatic lymph
nodes in patients with confirmed primary cancer. Foreign brand of
Combidex.
An ultrasmall superparamagnetic iron oxide under development as a
positive enhancing blood pool agent.
Investigational
42
47
Confirmed
Nano-Patterned Polyurethane Test Substrates
Superparamagnetic iron-oxide nanoparticles with unknown coating. Can

assist in the differentiation of metastatic and non-metastatic lymph
nodes in patients with confirmed primary cancer.
By use of a perfectly controlled nanoporous membrane, the drug can be

delivered from an implantable system over several weeks to several
months. The delivery profile can be tailored to specific pharmacokinetic
requirements by modification of the size as well as the thickness of the
membrane. Additional surface chemistry can be added to the membrane
in order to delay the delivery over a prolonged period of time.
In Vivo
41
A class of novel fullerenes comprising 80 carbons (C80) forming a sphere

which encloses a complex of three metal atoms and one nitrogen atom.
Carbon nanomaterials have the potential for use in diagnostics as safe
imaging agents and in therapeutics targeting and treating diseases.
Polymeric substrates are optically transparent and possess an
anisotropic topography on tens of nanometer scales. The substrates are
also available with conformal coatings of gold. When combined with the
use of self-assembled monolayers formed from organosulfur
compounds, these gold-coated polymeric substrates offer control of the
chemical functionality and nanometer-scale topography of surfaces. This
characteristic makes these substrates potentially useful in investigating a
range of surface-dominated phenomena.
Cadmium/selenium/tellurium core with zinc-sulfide shell and polymer
coating. Quantum dots provide fluorescent excitation under specific
wavelengths of light. Biomolecular targeting options availabe for specific
cells types. Multiple product lines available. For in vitro testing
applicaitons only.
Iron oxide nanoparticles with antibody, protein, or streptavidin
conjugation.
Custom conjugation of colloidal gold nanoparticles.
Custom conjugation of colloidal gold nanoparticles.
FeraSpin R is a nanoparticulate superparamagnetic iron oxide contrast
agent specifically formulated for pre-clinical magnetic resonance
imaging (MRI). FeraSpin R accumulates particularly in the liver and
spleen and is degraded with its iron being transferred into the
physiological iron stores.
Bioaffine ligands are covalently bound to magnetic particles.
Available in sizes from 20nm to 4um. Molecular Probes FluoSpheres and
TransFluoSpheres beads are manufactured using high-quality, ultraclean
polystyrene microspheres. These imicrospheres are internally labeled
with Molecular Probes dyes, making them the brightest fluorescent
microspheres available . Used as injectable tracers.
48
Invitrogen
Confirmed
FluoSpheres
Invitrogen
Exempt
In Vitro Diagnostic
Nanoparticle
20
Research Use
In Vitro
NA
In Vitro
Hard
NA
49
Nanoco
Confirmed
Nanodots
Nanoco Group PLC
Device
In Vitro Diagnostic
Quantum Dot
< 10
Research Use
In Vitro
NA
In Vitro
Hard
Active
Quantum dots for research use.
50
Project, Crystalplex
Confirmed
TriLite Nanocrystals
Crystalplex Corporation
Device
In Vitro Diagnostic
Quantum Dot
5-10
Research Use
In Vitro
NA
In Vitro
Hard
Active
Cadmium/selenium/sulfur core with various options for surface

functionalization and coatings. Quantum dots provide fluorescent
excitation under specific wavelengths of light. No biomolecular
targeting. Multiple product lines. For in vitro testing applicaitons only.
51
Wang, MR-TechIP
Confirmed
Clariscan
Nycomed
Drug
In Vivo Imaging
SPIO
20
Terminated
Intravenous
Passive
In Vivo
Hard
Active
Superparamagnetic iron-oxide nanoparticles with unknown coating.

Passive targeting of liver and tumors. Development was discontinued for
unlisted reasons.
52
Roszek, Z. Zhang (2001)
Confirmed
Implant Coatings
Inframat Inc.
Device
Device Coating
Nanocoating
20-50
Unknown
Implant
NA
Unknown
Nanostructured
Material
NA
Inframat is a global leader in nano/superfine coatings using techniques

of thermal spray, solution plasma spray, and electrodeposition. Coating
types include wear resistance, anti-corrosion, anti-biofouling, and high
lubricity coatings in both ceramic and hardmetal composites.
53
Roszek, Sato
Confirmed
IonTite
Spire Biomedical Corporation
Device
Device Coating
Nanocoating
20
Unknown
Implant
NA
In Vivo
Nanocrystal CaP
NA
Calcium phosphate formulations, coatings are ideal for promoting

bone/implant interfacial bonding. These adherent coatings can be
applied to dental, joint replacement and fixation products made of
biomaterials such as Co-Cr, Ti, stainless steel and most metals.
54
Debiotech, Roszek
Confirmed
Nanocoating
Debiotech SA
Device
Device Coating
Nanocoating
100
Unknown
Implant
NA
In Vivo
Nanostructured
Material
NA
Nanocoatings are used in the fields of drug eluting stents (DES) and
orthopaedic Implants. This coating technology can produce ceramic
coatings with variable chemistries, controlled porosities, large specific
surface areas and high drug loading capacity.
55
Masse, Roszek
Confirmed
Spi-Argent
Spire Biomedical Corporation
Device
Device Coating
Nanosilver
50-150
Unknown
Implant
NA
In Vivo
Hard
NA
Spi-Argent is a nanocrystalline silver-based antimicrobial coating that

can be applied to polymeric, ceramic or metallic medical devices. This
minimally-leaching film reduces the potential for bacterial colonization
without the drawbacks of other antimicrobials and antibiotics.
56
NCT00971373, Wong
Likely
Vestex Textiles (NanoSphere)
Vestagen Technical Textiles, LLC

Schoeller Technologies
Exempt
Healthcare Textile
Approved
2000
External
NA
Ex Vivo
Nanostructured
Material
NA
57
Wagner, Nymox
Likely
NicAlert
Nymox
Device
In Vitro Diagnostic
Colloidal Gold
Approved
Oct-02
In Vitro
NA
In Vitro
Hard
NA
Phase III
K021688
Nanostructured impregnation involves a three-dimensional surface

structure with gel-forming additives which repel water and prevent dirt
particles from attaching themselves.
Colloidal gold bound to antibodies for specific protein detection. Urine
and saliva based assay. Detects cotinine, the principle metabolite of
nicotine.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
58
Roszek
Likely
Stratus CS
Dade Behring
Device
In Vitro Diagnostic
59
OsSatura, Roszek
Likely
OsSatura
Isotis Orthobiologics US
Device
60
Project
Likely
Zirconium Oxide
Altair Nanotechnologies, Inc.
61
Wagner, KerrDental
Likely
Premise
Sybron Dental Specialties
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase

or Foreign Country
In Vivo Targeting
In Vivo
Use
Soft / Hard
Nanoparticle
Active
Nanotechnology
Dendrimer
Approved
Jan-03
K022976
In Vitro
NA
In Vitro
Soft
NA
Bone Substitute
Nanocomposite
Approved
May-03
K030131
Implant
NA
In Vivo
Nanocrystal HA
NA
Device
Dental Composite
Nanocomposite
Approved
Sep-03
Dental
NA
In Vivo
Hard
NA
Device
Dental Composite
Nanocomposite
Approved
Nov-03
Dental
NA
In Vivo
Hard
NA
K032921
62
Veridex
Likely
CellSearch Epithelial Cell Kit
Veridex, LLC (Johnson & Johnson)
Device
In Vitro Diagnostic
SPIO
Approved
Jun-04
K040898
In Vitro
NA
In Vitro
Hard
Active
63
Rivera Gil
Likely
NanOss
Angstrom Medica, Inc.
Device
Bone Substitute
Nanocomposite
Approved
Feb-05
K050025
Implant
NA
In Vivo
Nanocrystal HA
NA
64
Project, Greenberg
Likely
EnSeal Laparoscopic Vessel Fusion System
Ethicon Endo-Surgery, Inc.
Device
Device Coating
Nanoparticle Coating
Approved
Apr-05
K050671
Surgical
NA
In Vivo
Nanostructured Material
NA
65
Nano-Bond
Likely
Nano-Bond
Pentron Clinical Technologies, LLC
Device
Dental Composite
Nanocomposite
Approved
Implant
NA
In Vivo
Hard
NA
Aug-07
K071500
66
Dobson, Buxton
Likely
Verigene
67
BIOMET
Likely
NanoTite Implant
Nanosphere, Inc.
Device
In Vitro Diagnostic
Colloidal Gold
Approved
Sep-07
K070804
In Vitro
NA
In Vitro
Hard
NA
Device
Device Coating
Nanocomposite
Approved
Jan-08
K051461
Implant
NA
In Vivo
Nanocrystal CaP
NA
In Vitro Diagnostic
Nanoparticle
Approved
Mar-08
K073699
In Vitro
NA
In Vitro
Hard
NA
Biomet
68
Saladax
Likely
MyCare Assays
69
ETEX
Likely
70
ETEX
71
Saladax Biomedical
Device
Alpha-bsm
ETEX Corporation
Device
Bone Substitute
Nanocomposite
Approved
Nov-09
K091607
Implant
NA
In Vivo
Nanocrystal HA
NA
Likely
Beta-bsm
ETEX Corporation
Device
Bone Substitute
Nanocomposite
Approved
Nov-09
K091607
Implant
NA
In Vivo
Nanocrystal HA
NA
ETEX
Likely
EquivaBone
ETEX Corporation
Device
Bone Substitute
Nanocomposite
Approved
Nov-09
K091607
Implant
NA
In Vivo
Nanocrystal HA
NA
72
ETEX
Likely
Gamma-bsm
ETEX Corporation
Device
Bone Substitute
Nanocomposite
Approved
Nov-09
K091607
Implant
NA
In Vivo
Nanocrystal HA
NA
73
ETEX
Likely
CarriGen
ETEX Corporation
Device
Bone Substitute
Nanocomposite
Approved
Feb-10
K093447
Implant
NA
In Vivo
Nanocrystal HA
NA
74
Wagner
Likely
Mondial NanoPearls
Heraeus Kulzer
Device
Dental Composite
Nanocomposite
Approved
Dental
NA
In Vivo
Hard
NA
75
Roszek
Likely
Bioline 1RK91
Sandvik Materials Technology
Device
Surgical
Nanocomposite
Foreign Approval
Surgical
NA
In Vivo
Nanostructured
Material
NA
76
Hayman
Likely
Silverline
Spiegelberg KG
Device
Device Coating
Nanosilver
Foreign Approval
Surgical
NA
In Vivo
Hard
NA
77
Roszek
Likely
BrachySil
pSivida Ltd.
Device
Solid Tumors
Nanoporous Material
Investigational
Phase II
Interstitial
NA
In Vivo
Nanostructured
Material
NA
78
NCT00337714, Buxton
Likely
Corel-C Stent
Relysis Medicals
Device
Device Coating
Nanoparticle Coating
Investigational
Phase II
Implant
NA
In Vivo
Hard
NA
79
Roszek, Oncologic
Likely
Aspen Medisys, LLC (Formerly Targeted NanoTherapeuticsTM)
Triton BioSystems, Inc.
Device
Solid Tumors
SPIO
Investigational
Preclinical
In Vivo
Hard
Active

The Stratus CS Analyzer for acute care diagnostics provides quantitative
cardiac assays for fast, cost-effective evaluation of patients presenting
with suspected myocardial ischemia. Utilizes dendrimer-linked
antibodies.
Ossatura is composed of approximately 80% hydroxyapatite (HA) and
20% -tricalcium phosphate (-T CP), similar to human bone in both
structure and chemical composition.
Nanoscale zirconium-oxide particles used in dental fillings. High strength
and good optical imaging qualities.
0.4 micron barium glass filler along with nanoparticles for enhanced
polishability and gloss. The addition of pre-polymerized filler particles
(PPF) gives physical properties equivalent to a hybrid.
The CellSearch Epithelial Cell Kit contains a ferrofluid-based capture
reagent and immunofluorescent staining reagents. The ferrofluid
reagent consists of nanoparticles with a magnetic core surrounded by a
polymeric layer coated with antibodies targeting the Epithelial Cell
Adhesion Molecule (EpCAM) antigen for capturing circulating tumor cells
(CTCs).
Nanocrystalline hydroxyapatite forming solution which is injected into a
bone voids or defects to provide filling. The fill resorbs and is replaced
with bone during the healing process.
Surgical tissue sealing instrument. The device employs an electrode with
nanometer-sized conductive particles embedded in a proprietary
temperature-sensitive polymer that maintains tissue temperature at
around 100C.
Unique, functional, nano-particle that strengthens the resin while it
infiltrates the etched surface and provides a strong interface.
Surface functionalized colloidal gold nanoparticles for detection of
nucleic acid and protein targets.
Nanometer-scale discrete crystalline deposition (DCD) of calcium
phosphate (CaP) creates a complex surface topography. This renders the
NanoTite implant a bone bonding surface by the interlocking of the
newly formed cement.
Tests that measure chemotherapy drug levels in blood using proprietary
monoclonal antibodies bound to nanoparticles.
Dental composite incorporating "nanopearls," but unable to locate more
specific information on the composite construction.
It is a stainless grade, UNS 46910, alloyed with Mo, Ti, Cu and Al which
form nano-size precipitates. It offers a combination of high tensile and
stiffnes and excellent ductility which cannot be found in any other
stainless steel.
Cranial drainage catheters with silver nanoparticle, antimicrobial
coating.
BrachySil, (32P-BioSilicon), is a novel brachytherapy product currently
in development for the treatment of solid tumors. BrachySil comprises
30 micron particles of highly pure BioSilicon encapsulating radioactive
phosphorous (32P) closely bonded within an internal silicon
microcrystalline structure.
Paclitaxel-eluting porous carbon-carbon nanoparticle coated,
nonpolymeric cobalt-chromium coronary stent.
Aduro Biosciences merged with Triton BioSystems and Aspen Medisys,
LLC., which has now spun off to pursue magnetic nanoparticle heating
applications.
80
Roszek
Likely
Gadomer-17
Schering
Device
In Vivo Imaging
Dendrimer
Investigational
Preclinical
Intravenous
Passive
In Vivo
Soft
NA
An intravascular macromolecular MRI contrast agent with positive

enhancement under development for MR angiography and tumor
differentiation. The synthetic dendrimer with large molecular weight
(17kD - limits agent to vascular space) is linked to Gadolinium. Stucture
is likely on the order of several nanometers.
81
Buxton, NanoScan
Likely
N1177
NanoScan Imaging, LLC.
Device
In Vivo Imaging
Nanoparticle
Investigational
Preclinical
Intravenous
Passive
In Vivo
Hard
NA
Emulsified suspension that is composed of crystalline iodinated particles

dispersed with surfactant, selectively accumulates in macrophage cells.
82
Biophan
Likely
Nanomagnetic Enhanced Drug Delivery
Biophan Technologies, Inc.
Device
Drug Delivery
Nanoparticle
Investigational
Preclinical
Intravenous
Magnetic
In Vivo
Hard
Active
Nanomagnetic carriers offer the possibility of improved drug efficacy

and reduced toxicity by delivering pharmaceuticals to the exact location
of need and releasing them at the appropriate time.
In Vivo
Nanostructured
Material
NA
83
Nanovis
Likely
Nanostructured Coatings
Device
Tissue Engineering
Nanocoating
84
DiagNano
Likely
NanoHC
85
Yang
Likely
86
Dobson
87
Wagner, Nymox
Investigational
Preclinical
Nanovis
DiagNano
Exempt
In Vitro Diagnostic
Alert Ticket
US Army Research Laboratory
Device
In Vitro Diagnostic
Likely
Sensation Technology
Nanomix, Inc.
Device
Likely
TobacAlert
Nymox
Exempt
Quantum Dot
Investigational
Research Use
In Vitro
NA
In Vitro
Hard
Active
Dendrimer
Investigational
In Vitro
NA
In Vitro
Soft
NA
In Vitro Diagnostic
Carbon Nanotube
Investigational
In Vitro
NA
In Vitro
Hard
NA
In Vitro Diagnostic
Colloidal Gold
Research Use
In Vitro
NA
In Vitro
Hard
NA
Sep-03
Implant
NA
Nanovis nanostructured biomaterials are designed to act as highly

effective tissue scaffolds with customizable resorption profiles and
capability for localized drug delivery. Currently developing
nanostructured biomaterials using novel nanostructured polymers and
nanoscale ceramics as well as novel self assembling helical rosette
nanotubes.
Quantum dots for research use.
Alert TicketTM (US Army Research Laboratory, Adelphi, MD) is an
anthrax-detection agent.
Carbon nanotubes with biomolecular targeted, chemical surface
treatments for electronic detection of biological molecules.
Colloidal gold bonded to antibodies for specific protein detection. Urine
and saliva based assay. Detects cotinine, the principle metabolite of
nicotine. Not approved for medical use.
ID
References
Nanomedicine
Relevance
Product Name or ID
FDA Classification
88
Wagner, Nymox
Likely
AlzheimAlert
Nymox
Exempt
In Vitro Diagnostic
89
Wagner
Likely
AuroDye
GE Healthcare
Exempt
90
eBiosciences
Likely
eFluor Nanocrystals
91
Miltenyi
Likely
ExiTron
Nanoscale
Dimension (nm)
Status
Approval Date or
Phase
Colloidal Gold
Research Use
Jul-05
In Vitro Diagnostic
Colloidal Gold
Exempt
In Vitro Diagnostic
Exempt

or Foreign Country
In Vivo Targeting
In Vivo
Use
Soft / Hard
Nanoparticle
Active
Nanotechnology
In Vitro
NA
In Vitro
Hard
NA
Colloidal gold bound to antibodies for specific protein detection. Urine

based assay. Identifies neural thread protein (NTP), which is
overexpressed in patients with Alzheimer's disease.
Research Use
In Vitro
NA
In Vitro
Hard
NA
Colloidal gold reagent is a stabilized gold solution adjusted to a pH of

about 3. At this low pH, negatively charged gold particles bind very
selectively to proteins by hydrophobic and ionic interactions.
Quantum Dot
Research Use
In Vitro
NA
In Vitro
Hard
Active
In Vivo Imaging
Nanoparticle
Research Use
Intravenous
Passive
Animal
Hard
NA
Exempt
In Vitro Diagnostic
SPIO
Research Use
In Vitro
NA
In Vitro
Hard
Active
Exempt
In Vitro Diagnostic
Dendrimer
Research Use
In Vitro
NA
In Vitro
Soft
NA
Exempt
In Vitro Diagnostic
Dendrimer
In Vitro
NA
In Vitro
Soft
NA
NA
eBiosciences
Miltenyi Biotec
92
T2 Biosystems
Likely
NanoDX
93
EMD Chemicals
Likely
NanoJuice
94
Roszek
Likely
SuperFect
T2 Biosystems
EMD Chemicals Inc. (Dendritic
Nanotechnologies)
Qiagen
Research Use
95
ClinicalTrials.gov
Potential
ACUVUE
Johnson & Johnson
Device
Contact Lens
Hydrogel
Approved
Feb-00
K994324
Opthalmic
NA
In Vivo
Soft
96
ClinicalTrials.gov
Potential
Menicon Z
Menicon Co., Ltd.
Device
Contact Lens
Hydrogel
Approved
May-00
K000133
Opthalmic
NA
In Vivo
Soft
97
NCT01359046, CR Bard
Potential
Bardex IC Catheter
C. R. Bard, Inc.
Device
Device Coating
Hydrogel
Approved
Sep-02
K002612
Surgical
NA
Surgical
NA
98
Roszek, Deffenbaugh
Potential
Rheo Knee
Ossur
Device
External
NA
External
NA
Orthopedic
Nanoparticle
Approved
Jan-04
510k Exempt
100-1000
NA
99
ClinicalTrials.gov
Potential
PureVision
Bausch & Lomb
Device
Contact Lens
Hydrogel
Approved
May-05
K050948
Opthalmic
NA
In Vivo
Soft
NA
100
NCT00828412
Potential
EpiCeram Skin Barrier Emulsion
Promius Pharma, LLC
Device
Creams and Gels
Emulsion
Approved
Apr-06
K052643
Topical
NA
In Vivo
Soft
NA
101
Wagner
Potential
SYNOX
Biotronik
Device
Device Coating
Approved
Sep-08
K980869
Surgical
NA
Surgical
Jan-10
K093331
NA
102
NCT01188226
Potential
SR Phonares
Ivoclar Vivadent Inc.
Device
Dental Composite
Nanocomposite
Approved
Implant
NA
In Vivo
Hard
NA
103
ClinicalTrials.gov
Potential
ClearKone
SynergEyes, Inc.
Device
Contact Lens
Hydrogel
Approved
Opthalmic
NA
In Vivo
Soft
NA
104
ClinicalTrials.gov
Potential
OPTIX
Device
Contact Lens
Hydrogel
Approved
Opthalmic
NA
In Vivo
Soft
NA
105
ClinicalTrials.gov
Potential
VISA
Coopervision, Inc.
Device
Contact Lens
Hydrogel
Approved
Opthalmic
NA
In Vivo
Soft
NA
106
NCT00947726, CeraVe
Potential
CeraVe
CORIA Laboratories, Ltd.
Exempt
Creams and Gels
Emulsion
Commercial
Topical
NA
In Vivo
Soft
NA
107
Cinvention
Potential
cequence/celect/cimpact
Cinvention AG
Device
Device Coating
Nanocoating
Investigational
Preclinical
Implant
NA
In Vivo
Nanostructured
Material
NA
108
Roszek
Potential
NanoSpider Technology
HemCon Medical Technologies Inc.
Device
Wound Care
Nanofiber
Investigational
Preclinical
Wound Care
NA
External
109
Nanotope
Potential
Neural Tissue Regenerative Gel
Device
Tissue Engineering
Nanofiber
Investigational
Preclinical
Implant
NA
In Vivo
Biodegradable
NA
Preclinical
Implant
NA
In Vivo
Hard
NA
NA
Nanotope
eFluor Nanocrystals are high quantum yield nanocrystals that possess a

core particle surrounded by a patented surface coating that reduces
background staining and artifacts.
Alkaline earth metal-based nanoparticulate contrast agent specifically
formulated for preclinical computed tomography (CT).
Nanoparticles composed of an iron oxide metal core covered with
dextran polymer. These are in turn functionalized with a detection
moiety, such as a an antibody recognizing a virus.
Priostar dendrimers along with a polycationic liposomal formulation.
Transfection reagent.
SuperFect Transfection Reagent is based on activated dendrimer
technology developed for DNA transfection into a broad range of cell
lines.
Soft contact lenses made from hydrogels. Unable to confirm the size of
hydrogels, but hydrogel structure could be nanoscale.
Unable to confirm size of hydrogel or nanoparticles, but "silver hydogel"
coating could be nanoscale.
Description provided by Roszek notes that use of 100-1000 nm iron
particles in magnetorheologic fluid that is used for damping in the
prosthetic joint. Unable to find description of nanoparticle fluid
elsewhere.
Emulsion-based skin cream for treatment of chronic skin conditions
characterized by dryness, itching, and inflammation.
"Fractal" nanostructured coating on electrodes provides improved
electrical performance. No information or structural dimensions
provided for fractal coating.
Emulsion-based skin cream for treatment of chronic skin conditions
characterized by dryness, itching, and inflammation.
Manufacturer website indicates "nano-structured" coatings, but no clear
references on details of nanoscale nature of coatings.
The NanoSpider technology allows multiple fibers to be created and
spun together in both simple or complex layering configurations for use
in medical products.
These nanofiber gels are capable of directing the rapid differentiation of
immature neuroprogenitor cells into neurons with significant neurite
outgrowth.
The core NMS technology is a silicon-based nanofabricated chip that
contains nanochannels which regulate and/or control the molecule-bymolecule release of a therapeutic agent stored within the implant.
110
NanoMedicalSystems
Potential
Personalized Molecular Drug-delivery System

(PMDS)
NanoMedical Systems
Device
Implantable Drug Delivery
Investigational
111
Dobson
Potential
BioDetect
Integrated Nano-Technologies
Device
In Vitro Diagnostic
Nanowire
Investigational
In Vitro
NA
In Vitro
NA
112
Chipman, Ambri, Prashar
Potential
Ion Channel Switch (ICS) Sensor
In Vitro Diagnostic
Nanomembrane
Investigational
In Vitro
NA
In Vitro
NA
Ambri
Device
Investigational
In Vitro
NA
In Vitro
NA
In Vivo
NA
Specific details on technology are not listed, but described as a sitespecific drug delivery system, which will allow for delivery of therapeutic
agents directly to specific cells within the body, such as tumors.
Nanoscale electrode wires are bridged by DNA segments, creating a

"DNA wire" for detection.
A self-assembling, synthetic, two molecular layer bio-membrane, the
ICS acts like a biological switch and is capable of detecting a range of
biological and chemical substances such as drugs, hormones, bacteria,
DNA, and ions, in any body fluid, including whole blood, urine, and
saliva. No approved applications.
Molecular surface modification for antimicrobial action, cell
attachement, drug-elution, immobilization, etc. No approved devices
utilizing technology are listed.
113
Hayman
Potential
Molecular Surface Modification Technologies
Chameleon Scientific
Device
Device Coating
114
Myshko
Potential
NanoSyringe
Integrated Nano-Technologies
Device
115
Nanologix
Potential
BioNanoPore
Nanologix, Inc.
Exempt
In Vitro Diagnostic
Nanoporous Material
Research Use
In Vitro
NA
In Vitro
NA
Microbial detection system utilizing sandwiched-membrane petri dish

technology with nanoporous membrane for nutrient transfer.
116
Zuo
Potential
ViriChip
BioForce Nanosciences, Inc.
Exempt
In Vitro Diagnostic
Research Use
In Vitro
NA
In Vitro
NA
Nanopatterned array of biomolecular targets for biological detection

applications.
117
Wagner, Tetric EvoCeram
Questionable
Tetric EvoCeram
Ivoclar Vivadent
Device
Dental Composite
Nanocomposite
40-3000
Approved
Nov-04
K042819
Dental
NA
In Vivo
NA
Dental composite with filler particles ranging from nano to micro size.
118
Borg, Artimplant
Questionable
Artelon
Device
Tissue Engineering
Nanofiber
100+, 750
Approved
Sep-07
K071887
Implant
NA
In Vivo
NA
Electrospun scaffolds for tissue engineering. The diameter of the

electrospun fibers, studied by scanning electron microscopy, ranged
from 100 nm to a few lm, with an average diameter of 750 nm.
Device
In Vitro Diagnostic
NA
In Vitro
NA
In Vitro
NA
Oral
Passive
In Vivo
NA
In Vitro
NA
NA
NA
In Vitro
Wound Care
Wound Care
Wound Care
External
NA
NA
NA
NA
External
External
External
External
Investigational
Hard
Artimplant
119
Project
Questionable
Microarrays
CombiMatrix Corporation
120
Questionable
Abdoscan
Nycomed
Drug
In Vivo Imaging
SPIO
121
122
Bawa,
Project, Dobson
Questionable
Questionable
Controlled Flow Cavitation Process

NanoChip Technology
Five Star Technologies

Nanogen Inc.
Device
Exempt
Manufacturing Process
In Vitro Diagnostic
NA
NA
123
NanoBiotech
Questionable
Novasome
IGI Laboratories, Inc.
Device
Liposome
124
125
126
127
NCT00970697
NCT00971048
NCT00984022
NCT00562471
Unlikely
Unlikely
Unlikely
Unlikely
DuoDERM Hydrogel
Tegaderm
Aquacel
Adhibit
ConvaTec
3M Company
ConvaTec
Angiotech Pharmaceuticals
Device
Device
Device
Device
Medical Dressing
Medical Dressing
Medical Dressing
Creams and Gels
Hydrogel
Hydrogel
Hydrogel
Hydrogel
Approved
3500
Foreign Approval
Process
Research Use
500-700
2005
Jun-05
Unknown
Approved
Approved
Approved
Approved
In Vivo
Dec-97
Nov-04
Dec-09
K973689
K040890
K091034
Hard
NA
NA
NA
Soft
NA
NA
NA
NA
NA
Microarrays use a specially modified CMOS semiconductor to direct the

molecular assembly of a specific sequence of DNA bases in response to a
digital command. Each feature on the array (a microelectrode) is
digitally addressed to selectively generate acid, by means of an
electrochemical reaction.
through the gastrointestinal tract.
Uses a cavitation process to provide control at the "nanoscale."
Mirco-assay using DNA markers.
Novasome is a liposome adjuvant marketed for development of generic
drugs. No partnered applications are listed.
Hydrating hydrogel gel for wound care.
Transparent hydrogel wound dressing.
Hydrogel wound dressing.
Hydrogel based adhesion prevention gel.
ID
References
Nanomedicine
Relevance
Product Name or ID
128
NCT00234728
Unlikely
Hydrogel Patch
129
NCT01077765
Unlikely
Eutrophill
130
NCT01088685
Unlikely
Hydrogel Blister Patch
Johnson & Johnson
Nanoscale
Dimension (nm)
FDA Classification
Status
Teikoku Pharma USA
Device
Medical Dressing
Hydrogel
Approved
Sanofi-Aventis US LLC
Device
Cosmetic
Hydrogel
Investigational
Device
Medical Dressing
Hydrogel
Investigational
Approval Date or
Phase
Phase III

or Foreign Country
In Vivo Targeting
In Vivo
Use
Soft / Hard
Nanoparticle
Active
Nanotechnology
Wound Care
NA
External
Subcutaneous
NA
In Vivo
Biodegradable
NA
NA
Wound Care
NA
In Vivo
Soft
NA

Hydrogel occulative dressing.
Polyacrylamide hydrogel for reconstruction of facial lipoatrophy in HIVinfected patients.
Hydrogel blister dressing.
References:
Acusphere (Website). Cited: 2010 Sep 26. Available from:
http://www.acusphere.com/product/prod_ai850.html
AeroLEF Ph2a APS2008 (Website). Cited: 2012 Mar 27. Available from:
http://www.ymbiosciences.com/upload_files/AeroLEF_Ph2a_APS2008.pdf
Alakhov V, Klinski E, Li S, Pietrzynski G, Venne A, Batrakova E, et al. Block copolymer-based
formulation of doxorubicin. From cell screen to clinical trials. Colloids and surfaces B:
Biointerfaces. 1999; 16(1-4): 11334.
Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, et al. Atu027, a liposomal small
interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer
research. 2008; 68(23): 9788.
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and
biodistribution of polymeric nanoparticles. Molecular pharmaceutics. 2008; 5(4): 50515.
Ambri Biosensor Technology (Website). Cited: 2010 Sep 26. Available from:
http://203.202.29.92/content/display.asp?name=technology
Artimplant - Selected publications (Website). Cited: 2010 Sep 26. Available from:
http://www.artimplant.com/our-technology/selected-publications.html
Azaya Therapeutics Products (Website). Cited: 2012 Mar 27. Available from:
http://www.azayatherapeutics.com/about-us/products
Bandak S. Novavax Inc. (Website). 2005. Available from: http://www.assocham.org/nanobio/btpresentation/28march/Curing_the_Incurables/Novavax_%20Initiatives.ppt
Bao A. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic
and non-invasive imaging studies. J.Pharmacol.Exp.Ther. 2003; 308(2): 419.
Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotechnology Law &
Business. 2008; 5(2): 13555.
BBInternational (Website). Cited: 2010 Sep 26. Available from:
http://www.bbigold.com/default_1_home
Behr J, Zimmermann G, Baumgartner R, Leuchte H, Neurohr C, Brand P, et al. Lung deposition
of a liposomal cyclosporine A inhalation solution in patients after lung transplantation.
Journal of aerosol medicine and pulmonary drug delivery. 2009; 22(2): 12130.
BioDelivery Sciences International | Bioral Amphotericin B (Website). Cited: 2010 Sep 26.
Available from: http://www.bdsi.com/bioral_amphotericin_b.php
BIOMET 3i Implant Systems - NanoTiteTM Implant - Introduction (Website). Cited: 2010 Sep
26. Available from:
http://biomet3i.com/countries/en/directory/Index.cfm?PageId=123456789101&App=Yes&CF
ID=6725292&CFTOKEN=64655598
Bio-Path Holdings, Inc. - Products - BP-100-2.01 (Website). Cited: 2011 May 12. Available
from: http://www.biopathholdings.com/prodpipeline.html
Biophan (Website). Cited: 2011 May 12. Available from:
http://www.biophan.com/index.php?option=com_content&task=view&id=363&Itemid=361
BioSante Pharmaceuticals - Products (Website). Cited: 2012 Mar 27. Available from:
http://www.biosantepharma.com/Products.php
Bissett D, Cassidy J, de Bono JS, Muirhead F, Main M, Robson L, et al. Phase I and
pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of
camptothecin (CPT). Br J Cancer. 2004 Jun; 91(1): 505.
Blue Membranes: Products: Medical Devices: Drug Delivery Coatings (Website). Cited: 2010
Sep 26. Available from: http://bluemembrane.com/?page=prod/med/index
Booser DJ. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant
breast cancer. Cancer Chemother.Pharmacol. 2002; 50(1): 6.
Borg E, Frenot A, Walkenstrm P, Gisselflt K, Gretzer C, Gatenholm P. Electrospinning of
degradable elastomeric nanofibers with various morphology and their interaction with human
fibroblasts. J. Appl. Polym. Sci. 2008 Apr; 108(1): 4917.
Buxton DB. Current status of nanotechnology approaches for cardiovascular disease: a personal
perspective. Wiley interdisciplinary reviews: Nanomedicine and nanobiotechnology. 2009;
1(2): 149.
C.R. Bard, Inc. Bard Medical - BARDEX I.C. Drainage Bag Foley Tray (Website). Cited:
2012 Mar 27. Available from: http://bardmedical.com/BARDEXICDrainageBagFoleyTray
Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. 2008.
Canelas DA, Herlihy KP, DeSimone JM. Top-down particle fabrication: control of size and
shape for diagnostic imaging and drug delivery. Wiley Interdisciplinary Reviews:
Nanomedicine and Nanobiotechnology. 2009; 1(4): 391404.
Capsulution: Nanocapsules (Website). Cited: 2012 Mar 27. Available from:
http://www.capsulution.com/en/established-technology/nanocapsules.html
Caruthers SD, Cyrus T, Winter PM, Wickline SA, Lanza GM. Anti-angiogenic perfluorocarbon
nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdisciplinary Reviews:
Nanomedicine and Nanobiotechnology. 2009; 1(3): 31123.
Ceram-X: Nano Ceramic Restorative (Website). Available from:

http://www.dentsply.es/Formacion/LiveUpdate1/CeramX/Product%20Brochure%20CeramX.
pdf
CeraVe: MVE Patented Technology (Website). Coria Laboratories, Ltd. Cited: 2012 Mar 27.
Available from: http://www.corialabs.com/mve.htm
Cereda CMS, De Araujo DR, Brunetto GB, De Paula E. Liposomal prilocaine: Preparation,
characterization, and in vivo evaluation. J Pharm Pharmaceut Sci. 2004; 7: 23540.
Cerulean Nanopharmaceuticals, Nanoparticle Design & Development (Website). Cerulean
Pharma Inc. Cited: 2012 Mar 27. Available from:
http://www.ceruleanrx.com/scienceNanopharmaceuticals.html
Chang S. A novel vaccine adjuvant for recombinant flu antigens. Biologicals. 2009; 37(3): 141.
chemicell GmbH. Ferrofluids: Ferromagnetic Particles in Carrier Fluid: Fluidmag Affinity
(Website). Cited: 2012 Mar 27. Available from:
http://www.chemicell.com/products/nanoparticles/fluidmag-affinity/index.html
Chipman SD, Oldham FB, Pezzoni G, Singer JW. Biological and clinical characterization of
paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymerdrug conjugate.
international Journal of Nanomedicine. 2006; 1(4): 375.
Chow T-H, Lin Y-Y, Hwang J-J, Wang H-E, Tseng Y-L, Pang VF, et al. Therapeutic Efficacy
Evaluation of 111In-Labeled PEGylated Liposomal Vinorelbine in Murine Colon Carcinoma
with Multimodalities of Molecular Imaging. J Nucl Med. 2009 Dec 1; 50(12): 207381.
Chu TC. Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a
potential ocular hypotensive agent. Journal of ocular pharmacology and therapeutics. 2002;
18(6): 507.
Chu Z. Saposin C: Neuronal Effect and CNS Delivery by Liposomes. Annals of the New York
Academy of Sciences. 2005 Aug; 1053(1): 23746.
Cinvention AG (Website). Cited: 2010 Sep 26. Available from:
http://www.cinvention.de/index.php?option=com_content&task=view&id=67&Itemid=125
Clark A, Rossiter-Rooney M, Chan V, Valle-Leutri F, Pliura D. Aerosolized Free and LiposomeEncapsulated Fentanyl (AeroLEFTM) via pulmonary administration allows patients with
moderate to severe post-surgical acute pain to self-titrate (Website). Available from:
http://www.ymbiosciences.com/upload_files/AeroLEF_Ph2a_APS2008.pdf
Constantinides PP. Advances in the Use of Lipid-Based Systems for Parenteral Drug Delivery.
2007. Available from:
http://www.cornerstonepharma.com/publications/constantinides_0608.pdf
Crystalplex Quantum Dots, Semiconductor Nanocrystals & Encoded Polystyrene Beads

(Website). Cited: 2011 May 11. Available from: http://www.crystalplex.com/
Danhauser-Riedl S, Hausmann E, Schick H-D, Bender R, Dietzfelbinger H, Rastetter J, et al.
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOXOXD). Invest New Drugs. 1993; 11(2-3): 18795.
Davis ME, others. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature
Reviews Drug Discovery. 2008; 7(9): 77182.
de Araujo DR. Pharmacological and local toxicity studies of a liposomal formulation for the
novel local anaesthetic ropivacaine. J.Pharm.Pharmacol. 2008; 60(11): 1449.
Debbage P, Jaschke W. Molecular imaging with nanoparticles: giant roles for dwarf actors.
Histochem Cell Biol. 2008 Sep; 130(5): 84575.
Debiotech - Medical Devices - Switzerland (Website). Cited: 2010 Sep 26. Available from:
http://www.debiotech.com/debiotech.html
DiagNano - Technology | DiagNano: Revolutionizing Diagnostics through Nanotechnology
(Website). Cited: 2010 Sep 26. Available from: http://www.nanohc.com/technology.html
DNA Nanoparticles (Website). Copernicus Theraputics - PLASminTM. Cited: 2012 Mar 27.
Available from: http://168.144.36.118/technology/plasmin.asp
Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nature
nanotechnology. 2007; 2(8): 46978.
Dobson MG. Emerging technologies for point-of-care genetic testing. Expert Review of
Molecular Diagnostics. 2007; 7(4): 359.
eBiosciences: eFluor Nanocrystals (Website). Cited: 2010 Sep 26. Available from:
http://www.ebioscience.com/ebioscience/efluornanocrystals.asp
EMD Chemicals USA | NanoJuice Transfection Reagent Kit - EMD4Biosciences (Website).
Cited: 2010 Sep 26. Available from: http://www.emdchemicals.com/life-scienceresearch/nanojuice-transfection-reagentkit/c_di6b.s1OJ7gAAAEhxawsgl8m?PortalCatalogID=merck4biosciences&CountryName=U
SA
Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. Journal of
Drug Targeting. 2007 Jan; 15(3): 16383.
Epeius Biotechnologies - Targeting Cancer from the Inside (Website). Cited: 2011 May 11.
Available from: http://www.epeiusbiotech.com/oncology-targeting.asp
ETEX products are composed of a proprietary nanocrystalline calcium phosphate formulation

that mimics the crystalline mineral structure of human bone (Website). Cited: 2011 May 11.
Available from: https://secure.etexcorp.com/products_overview.html
Eurand | Pharmaceutical Technologies (Website). Cited: 2010 Sep 26. Available from:
http://www.eurand.com/tech.html
Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorganic & medicinal chemistry.
2009; 17(8): 295062.
Filtek Supreme Plus Universal Restorative: A True Nanocomposite (Website). 2005. Available
from:
http://multimedia.3m.com/mws/mediawebserver?mwsId=66666UuZjcFSLXTtMxTtoXMyEV
uQEcuZgVs6EVs6E666666-Flamel Technologies (Website). Medusa Technology Platform. Cited: 2012 Mar 27. Available
from: http://www.flamel.com/technology-platforms/medusa/
Flamel Technologies, Inc (Website). Cited: 2010 Sep 26. Available from:
http://www.flamel.com/techAndProd/medusa.shtml
Fox CB. Squalene Emulsions for Parenteral Vaccine and Drug Delivery. Molecules. 2009 Sep;
14(9): 3286312.
Fukumori Y, Ichikawa H. Nanoparticles for cancer therapy and diagnosis. Advanced Powder
Technology. 2006; 17(1): 128.
Garci-a-Gallont R. Impact of C2 measurement on cyclosporine neoral dosing in a LatinAmerican transplant program: the Guatemalan experience. Transplant.Proc. 2004; 36(2):S451.
Gelmon KA. Phase I study of liposomal vincristine. Journal of clinical oncology. 1999; 17(2):
697.
Gil PR. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds.
Pharmacological research (Website). 2010; Available from:
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WP9-4Y7P4MJ-13&_cdi=6985&_user=616288&_pii=S104366181000023X&_orig=search&_coverDate=01%
2F25%2F2010&_sk=999999999&view=c&wchp=dGLzVtbzSkWA&md5=e1a7b4a57e189ee42e3594be817382d8&ie=/sdarticle.pdf
Glck R, Wlti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with
immunopotentiating reconstituted influenza virosomes (IRIV). Dev Biol (Basel). 2000; 103:
18997.
Greenberg JA. Product: EnSealTM. Rev Obstet Gynecol. 2009; 2(3): 2067.
Griese N. Determination of free and liposome-associated daunorubicin and daunorubicinol in
plasma by capillary electrophoresis. Journal of chromatography A. 2002; 979(1-2): 379.
Guggenbichler JP. Central Venous Catheter Associated Infections Pathophysiology, Incidence,

Clinical Diagnosis, and Prevention-A Review. Materialwissenschaft und Werkstofftechnik.
2003; 34(12): 1145.
Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, et al. Antitumor
effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed
monoclonal antibody GAH, in colorectal cancer xenografts. Cancer science. 2004; 95(7):
60813.
Han J. Physical properties and stability of two emulsion formulations of propofol. Int.J.Pharm.
2001; 215(1-2): 207.
Hayashi H, Uchiyama N, Kawamata H, Takagi R, Abe Y, Kumazaki T. Interaction between
Non-ionic Contrast Medium and Prostaglandin E1 Incorporated in Lipid Microspheres: Invitro Comparative Study of Direct and Non-direct Mixing. Radiation medicine. 2000; 18(4):
21926.
Hayat MA. Cancer imaging: Instrumentation and applications. Academic Press; 2007.
Hayman ML. The Emerging Product and Patent Landscape for Nanosilver-Containing Medical
Devices. Nanotechnology Law & Business. 2009; 148: 148158.
Heidel JD, Yu Z, Liu JY., Rele SM, Liang Y, Zeidan RK, et al. Administration in non-human
primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide
reductase subunit M2 siRNA. Proceedings of the National Academy of Sciences. 2007;
104(14): 5715.
Herringson TP, Altin JG. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator
lipid-anchored molecules. Journal of Controlled Release. 2009; 139(3): 22938.
Hosokawa T. Formulation Development of a Filter-Sterilizable Lipid Emulsion for Lipophilic
KW-3902, a Newly Synthesized Adenosine A 1-Receptor Antagonist. Chemical
pharmaceutical bulletin. 2002; 50(1): 87.
Huang Z, HUANG. Development and evaluation of lipid nanoparticles for camptothecin
delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid
emulsion. Acta pharmacologica Sinica. 2008; 29(9): 1094.
Huckriede A. The virosome concept for influenza vaccines. Vaccine. 2005; 23: S26.
IGI Laboratories, Inc. Novasome (Website). Cited: 2012 Mar 27. Available from:
http://www.igilabs.com/patented-technology/novasome
Ino Y, Guan Y, Nishiyama N, Cabral H, Koyama H, Kataoka K, et al. Development of novel
polymeric micelle drug carrier systems for brain tumor therapy. Proceedings of the American
Association for Cancer Research. 2005; 2005(1): 330.
Invitrogen: Labeled Beads (Website). Cited: 2010 Sep 26. Available from:
http://products.invitrogen.com/ivgn/en/US/adirect/invitrogen?cmd=catDisplayStyle&catKey=
89201&filterDispName=Labeled%2BBeads&_bcs_=H4sIAAAAAAAAAM2P3WrDMAyFn
8Y3CwlODJt7ma5klLIxKNu9sdXEEP9gOwl5%2B8ndWsZWdj0wEjqy%0ApO%2BUNaH8
NTg1yRQL0twXRwizlhD%2F0IeUPGEtaTp8y7JU2s46BdeDraQzKEadANMUMYDFMDiT
hcvG%0AUlhVXjc2Xev9qKVI2tlYDcmMeIU0LD%2FKU5gg1%2FSBYqppjQOcb2h9h%2
BUWhDoDCoNM2%2BJZy%2BCiHyD8%0ARvVf13%2FyspZTbOu5txfetyMGoXQAmXL
rOkBYJ40ibLd%2Ff3pB4p2OfhTro0jQu7AiCIoHWPHHmfG7%0AkZMY420nOW%2Fop6
P%2F5CAz3XLwAdAKxxU3AgAA
Ito I. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor
activity against human lung cancer in vivo. Cancer Gene Ther. 2004; 11(11): 733.
Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, et al. Pegylated arginine
deiminase treatment of patients with unresectable hepatocellular carcinoma: results from
phase I/II studies. Journal of clinical oncology. 2004; 22(10): 181522.
Jain V, Vyas SP, Kohli DV. Well-defined and potent liposomal hepatitis B vaccines adjuvanted
with lipophilic MDP derivatives. Nanomedicine: Nanotechnology, Biology and Medicine.
2009; 5(3): 33444.
Jamil H, Sheikh S, Ahmad I. Liposomes: the next generation. Modern Drug Discovery. 2004; 7:
369.
JV St. John, EH Callahan. Calculation, Measurement and Optimization of Pressure Decrease
Through Capillary Forces at a Powder Wound Dressing-Wound Interface. 2009 Diabetic
Limb Salvage Meeting (Website). 2009. Available from:
http://www.altrazeal.com/assets/3b_JSt_John_Negative_Pressure_G_Print.pdf
Kanaoka E. A novel and simple type of liposome carrier for recombinant interleukin-2.
J.Pharm.Pharmacol. 2001; 53(3): 295.
Kereos | Targeted Therapeutics and Molecular Imaging (Website). Cited: 2010 Sep 26. Available
from: http://www.kereos.com/
Khemtong C, Kessinger CW, Gao J. Polymeric nanomedicine for cancer MR imaging and drug
delivery. Chem. Commun. 2009; (24): 3497.
Knight V. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous
xenografts and pulmonary cancer metastases in mice. Ann.N.Y.Acad.Sci. 2006; 922: 151.
Koizumi F. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular
endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66(20): 10048.
Li L, Shen Y. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert
Opin. Biol. Ther. 2009 May; 9(5): 60919.
Li W. Lower Extremity Deep Venous Thrombosis: Evaluation with Ferumoxytol-enhanced MR

Imaging and Dual-Contrast MechanismPreliminary Experience1. Radiology. 2007;
242(3): 873.
Lindner LH. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes:
Active ingredient and mediator of drug release. J.Controlled Release. 2008; 125(2): 112.
Liquidia Technologies (Website). Cited: 2010 Sep 26. Available from:
http://www.liquidia.com/ProductPlatform.html
Lu S, LU. Construction, application and biosafety of silver nanocrystalline chitosan wound
dressing. Burns. 2008; 34(5): 623.
Lbbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical
experiences with magnetic drug targeting: a phase I study with 4-epidoxorubicin in 14
patients with advanced solid tumors. Cancer research. 1996; 56(20): 4686.
Luna nanoWorks | Nanotechnology - Carbon Nanomaterials (Website). Cited: 2010 Sep 26.
Available from: http://www.lunananoworks.com/products/trimetaspheres.asp
Magnetic Resonance Technology IP. Contrast Agents - Overview (Website). Cited: 2012 Mar
27. Available from: http://www.mr-tip.com/serv1.php?type=coa&sub=1
Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomes as carriers for tretinoinPreparation and properties. International journal of pharmaceutics. 2002; 234(1): 23748.
Masse A, Bruno A, Bosetti M, Biasibetti A, Cannas M, Gallinaro P. Prevention of pin track
infection in external fixation with silver coated pins: clinical and microbiological results.
Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2000; 53(5): 6004.
Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and
pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG
immunoliposome, in patients with metastatic stomach cancer. Annals of Oncology. 2004;
15(3): 517.
Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial
and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British
journal of cancer. 2004; 91(10): 177581.
Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating
polymer micelles. Cancer science. 2009; 100(4): 5729.
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer research. 1986; 46(12 Part 1): 6387.
Matsumura Y. Preclinical and clinical studies of anticancer drug-incorporated polymeric
micelles. Journal of Drug Targeting. 2007 Jan; 15(7-8): 50717.
Mayer LD. Optimizing combination chemotherapy by controlling drug ratios. Molecular

interventions. 2007; 7(4): 216.
Mebiopharm - Product & Technologies (Website). Cited: 2010 Sep 26. Available from:
http://www.mebiopharm.com/english/pro.html
Medical applications of liposomes. Amsterdam; New York: Amsterdam; New York: Elsevier;
1998.
Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes IAM, Zurlo
MG, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble
polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs. 2001; 12(4): 315.
Miltenyi Biotec - FeraSpin (Website). Cited: 2010 Sep 26. Available from:
http://www.miltenyibiotec.com/en/PG_836_1108_feraspin_r,_mri_contrast_agent.aspx
Mischler R. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine.
2002; 20: B17.
ML Ratner. Mersana Therapeutics Inc. START-UP: Windhovers Review of Emerging Medical
Ventures (Website). 2006; Available from:
http://www.puretechventures.com/images/news/pdfs/Mersana%20in%20Start%20Up%20mag
azine.pdf
Morgan LR, Struck RF, Waud WR, LeBlanc B, Rodgers AH, Jursic BS. Carbonate and
carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer
Chemother Pharmacol. 2009 Mar; 64(4): 82935.
Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for
infectious disease. Current pharmaceutical design. 2002; 8(6): 44154.
Morse M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Current Opinion in
Molecular Therapeutics. 2005; 7(2): 164.
Mraz S. A new buckyball bounces into town (Website). Cited: 2010 Sep 26. Available from:
http://machinedesign.com/article/a-new-buckyball-bounces-into-town-0414
Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr.Oncol.Rep.
2001; 3(2): 156.
Myshko D. Nanotechnology: Its a Small World. PharmaVOICE. 2004 Feb.
NanoBio Corporation - NanoStatT Platform (Website). Cited: 2012 Mar 27. Available from:
http://www.nanobio.com/Platform-Technology/NanoStat-Platform.html
Nanobiotx. Technology / Products | nanobiotix (Website). Cited: 2012 Mar 27. Available from:
http://www.nanobiotix.com/technology-products/#nanoXray
Nano-Bond: Nano Particulate Reinforced Adhesive System. Pentron Clinical Technologies,

LLC; 2008. Report No.: ACLT_Rev01.
NanoCarrier | Pipeline | Research and Development (Website). Cited: 2010 Sep 26. Available
from: http://www.nanocarrier.co.jp/en/research/pipeline/index.html
Nanoco Technologies (Website). Cited: 2010 Sep 26. Available from:
http://www.nanocotechnologies.com/content/Products/CadmiumBasedQuantumDotsNanoDot
s.aspx
NanoCyte: Products (Website). Cited: 2010 Sep 26. Available from: http://www.nanocyte.com/products.html
NanoDx Nanoparticles T2 Biosystems (Website). Cited: 2011 Feb 10. Available from:
http://www.t2biosystems.com/Site/ScienceTechnology/T2BiosystemsproprietaryNanoparticle
s/tabid/64/Default.aspx
Nanologix. BioNanoPore (BNP) Rapid Test Kits (Website). Cited: 2012 Mar 27. Available from:
http://nanologix.com/products/BNP.html
NanoMedical Systems (Website). Cited: 2010 Sep 26. Available from:
http://www.nanomedsys.com/
NanoScan Imaging, LLC. N1177 (Website). Cited: 2012 Mar 27. Available from:
http://www.nanoscanimaging.com/n1177.html
Nanotechnology and Medicine / Nanotechnology Medical Applications (Website). The Project
on Emerging Nanotechnologies. Cited: 2011 May 11. Available from:
http://www.nanotechproject.org/inventories/medicine/
Nanotope (Website). Cited: 2010 Sep 26. Available from: http://www.nanotope.com/product.php
Nanovis Incorporated (Website). Cited: 2010 Sep 26. Available from:
http://www.nanovisinc.com/researchdevelopment.html
NCT00000847. A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox
ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
(Clinical Trial). ClinicalTrials.gov.
NCT00000847. A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox
ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
NCT00001512. Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived
Immunoglobulin Idiotype Antigen Vaccines (Clinical Trial). ClinicalTrials.gov.
NCT00002742. Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment
for Hematologic Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00004083. Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer

NCT00004104. Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in
Treating Patients With Stage III Melanoma (Clinical Trial). ClinicalTrials.gov.
NCT00004471. Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic
Liposome Mediated Gene Transfer (Clinical Trial). ClinicalTrials.gov.
NCT00004806. Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic
Fibrosis (Clinical Trial). ClinicalTrials.gov.
NCT00005969. Liposomal Tretinoin in Treating Patients With Recurrent or Refractory
Hodgkins Disease (Clinical Trial). ClinicalTrials.gov.
NCT00009841. Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00024492. Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With
Advanced Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00024648. Study to Determine Maximum Tolerated Dose of LErafAON Combined With
Radiotherapy in Patients With Advanced Malignancies (Clinical Trial). ClinicalTrials.gov.
NCT00035867. Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
NCT00038207. Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed
Malignancies (Clinical Trial). ClinicalTrials.gov.
NCT00046787. Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat
Recurrent Small Cell Lung Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00053716. Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for
Peripheral Arterial Occlusive Disease (Clinical Trial). ClinicalTrials.gov.
NCT00055133. A Study Using Intravenous PaxceedTM to Treat Patients With Rheumatoid
Arthritis (Clinical Trial). ClinicalTrials.gov.
NCT00059605. Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer
NCT00059657. Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg
Ischemia Due to Peripheral Arterial Disease (Clinical Trial). ClinicalTrials.gov.
NCT00089180. T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin
Cancer in Patients Who Have Undergone a Kidney Transplant (Clinical Trial).
ClinicalTrials.gov.
NCT00096668. Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial

Treatment for Metastatic Breast Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00104754. Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer (Clinical
Trial). ClinicalTrials.gov.
NCT00117429. Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With
Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) (Clinical Trial).
ClinicalTrials.gov.
NCT00143611. Efficacy & Safety of Resatorvid in Adults With Severe Sepsis (Clinical Trial).
ClinicalTrials.gov.
NCT00144963. Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or
Refractory Acute Lymphoblastic Leukemia (Clinical Trial). ClinicalTrials.gov.
NCT00157209. Phase IIb Randomized Controlled Study of BLP25 Liposome Vaccine for
Immunotherapy of Non-Small Cell Lung Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00175877. A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in
the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint
Damage in Patients With Active Rheumatoid Arthritis (Clinical Trial). ClinicalTrials.gov.
NCT00234728. Study of a New Dressing for Use With Topical Medications (Clinical Trial).
ClinicalTrials.gov.
NCT00245297. Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS)
Reconstituted in Pegylated Liposomes (Clinical Trial). ClinicalTrials.gov.
NCT00271063. Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute
Lymphocytic Leukemia (Clinical Trial). ClinicalTrials.gov.
NCT00291603. Short Term Effects of FX Dialysers on QOL and Inflammation (Clinical Trial).
ClinicalTrials.gov.
NCT00308711. Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for
Cervical Ripening and Induction of Labor (Clinical Trial). ClinicalTrials.gov.
NCT00328692. PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment
Effect on Congestion and Renal Function (Clinical Trial). ClinicalTrials.gov.
NCT00332462. A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine
in de Novo Liver Transplant Recipients (Clinical Trial). ClinicalTrials.gov.
NCT00337714. Comparison of Central Venous Catheters With Silver Nanoparticles Versus
Conventional Catheters (Clinical Trial). ClinicalTrials.gov.
NCT00337714. Comparison of Central Venous Catheters With Silver Nanoparticles Versus

Conventional Catheters (Clinical Trial). ClinicalTrials.gov.
NCT00356980. TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors
NCT00361842. Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection
In Patients With Advanced Colorectal Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00364143. Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced
Solid Tumors (Clinical Trial). ClinicalTrials.gov.
NCT00364676. Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, NonHodgkins Lymphoma or Hodgkins Disease (Clinical Trial). ClinicalTrials.gov.
NCT00385177. Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With
Advanced Solid Tumors (Clinical Trial). ClinicalTrials.gov.
NCT00400348. Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion in
Patients With Ovarian Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00406341. Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
NCT00408668. Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP
Prime Boost Regimen (Clinical Trial). ClinicalTrials.gov.
NCT00432562. A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients
With Advanced Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00445419. Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides (Clinical
NCT00455052. A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
NCT00460525. Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali (Clinical Trial).
ClinicalTrials.gov.
NCT00481884. Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation
Dermatitis in Breast Cancer Patients (Clinical Trial). ClinicalTrials.gov.
NCT00484120. Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for
Knee OA Pain (Clinical Trial). ClinicalTrials.gov.
NCT00484120. Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for
Knee OA Pain (Clinical Trial). ClinicalTrials.gov.
NCT00492141. Aerosol L9-NC and Temozolomide in Ewings Sarcoma (Clinical Trial).

ClinicalTrials.gov.
NCT00505713. Safety and Efficacy Study Using Rexin-G for Sarcoma (Clinical Trial).
ClinicalTrials.gov.
NCT00533637. Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic
Rhinitis (Clinical Trial). ClinicalTrials.gov.
NCT00556946. Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains
NCT00562471. Safety and Efficacy Study of a Hydrogel, Applied Following Removal of
Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of
Postoperative Adhesion Formation (Clinical Trial). ClinicalTrials.gov.
NCT00611403. Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK
Patients (Clinical Trial). ClinicalTrials.gov.
NCT00617981. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in
Treatment of Hepatocellular Carcinoma (HCC) (Clinical Trial). ClinicalTrials.gov.
NCT00631631. L-MTP-PE for High-Risk Osteosarcoma (Clinical Trial). ClinicalTrials.gov.
NCT00646230. Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant
Neuroblastoma (Clinical Trial). ClinicalTrials.gov.
NCT00664170. A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in
Patients With Advanced Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00666328. Clevidipine in the Treatment of Patients With Acute Hypertension and
Intracerebral Hemorrhage (Clinical Trial). ClinicalTrials.gov.
NCT00672165. Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized AntiCD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
NCT00688519. Study to Compare U0267 Against Vehicle in Subjects With Plaque-type
Psoriasis (Clinical Trial). ClinicalTrials.gov.
NCT00689065. Safety Study of CALAA-01 to Treat Solid Tumor Cancers (Clinical Trial).
ClinicalTrials.gov.
NCT00690833. Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects
With Atopic Dermatitis (Clinical Trial). ClinicalTrials.gov.
NCT00709254. Study of Single and Multiple Doses of Inhaled AeroLEF (LiposomeEncapsulated Fentanyl)in Healthy Subjects (Clinical Trial). ClinicalTrials.gov.
NCT00739466. Biorest Liposomal Alendronate With Stenting sTudy (BLAST) (Clinical Trial).
ClinicalTrials.gov.
NCT00747474. Phase I Study of Intravenous Lipotecan (TLC388 HCl for Injection) in Patients
With Advanced Solid Tumors (Clinical Trial). ClinicalTrials.gov.
NCT00764361. Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity
Ulcers (Clinical Trial). ClinicalTrials.gov.
NCT00765973. Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian
Cancer and Other Advanced Solid Tumors (Clinical Trial). ClinicalTrials.gov.
NCT00769093. Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With
Recurrent High Grade Glioma Receiving Chemotherapy (Clinical Trial). ClinicalTrials.gov.
NCT00775138. A Study to Determine the Safety and Tolerability of ArikaceTM Versus Placebo
in Patients Who Have Bronchiectasis (Clinical Trial). ClinicalTrials.gov.
NCT00814515. Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in
Patients With Moderate to Severe Dry Eye Syndrome (Clinical Trial). ClinicalTrials.gov.
NCT00816829. Effect of Fenofibrate on Sleep Apnea Syndrome (Clinical Trial).
ClinicalTrials.gov.
NCT00828711. Misoprostol Vaginal Insert (MVI) 100, 150, 200 Mcg for Cervical Ripening and
Induction of Labor (Clinical Trial). ClinicalTrials.gov.
NCT00860522. JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
NCT00875693. A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning
(RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory
and Relapsed Acute Myelogenous Leukemia (AML) (Clinical Trial). ClinicalTrials.gov.
NCT00880802. Clinical Study of Antibacterial Nanoparticles Incorporated in Composite
Restorations (Clinical Trial). ClinicalTrials.gov.
NCT00880802. Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for
Rapid Assessment of Cardiac Ischemic Symptoms (Clinical Trial). ClinicalTrials.gov.
NCT00912574. Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma
Patients and in Sentinel Lymph Nodes: MEL38 (Clinical Trial). ClinicalTrials.gov.
NCT00912574. Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma
Patients and in Sentinel Lymph Nodes: MEL38 (Clinical Trial). ClinicalTrials.gov.
NCT00915187. Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza

Vaccine in Elderly (Clinical Trial). ClinicalTrials.gov.
NCT00922363. Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given
With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months
Interval to Healthy Adult Volunteers (Clinical Trial). ClinicalTrials.gov.
NCT00927459. Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and
Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol (Clinical
NCT00940758. Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to
1st-line Oxaliplatin Base Therapy (Clinical Trial). ClinicalTrials.gov.
NCT00947726. Ceramide Containing Multivesicular Emulsion Application (Clinical Trial).
ClinicalTrials.gov.
NCT00952692. Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With
Lapatinib to Patients With Metastatic Breast Cancer (Clinical Trial). ClinicalTrials.gov.
NCT00964080. Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or
Esophageal Adenocarcinoma (Clinical Trial). ClinicalTrials.gov.
NCT00968604. C-VISA BikDD: Liposome in Advanced Pancreatic Cancer (Clinical Trial).
ClinicalTrials.gov.
NCT00970697. Becaplermin Gel for MARTORELLs Hypertensive Leg Ulcers (Clinical Trial).
ClinicalTrials.gov.
NCT00971048. Evaluation of the Effects of HP828-101 Versus Standard of Care in the
Management of Partial or Full Thickness Wounds (Clinical Trial). ClinicalTrials.gov.
NCT00971373. Pilot Study to Determine the Effectiveness of Antimicrobial Healthcare
Workers (HCW) Hands and Clothing (Clinical Trial). ClinicalTrials.gov.
NCT00981006. AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic
cArdiomyopathy (ALCADIA) (Clinical Trial). ClinicalTrials.gov.
NCT00984022. Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision
and Drainage (Clinical Trial). ClinicalTrials.gov.
NCT01003288. Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen (Clinical Trial).
ClinicalTrials.gov.
NCT01007240. Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium
Polyethylenimine Nanoparticles (Clinical Trial). ClinicalTrials.gov.
NCT01007240. Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric
Atopic Dermatitis (Clinical Trial). ClinicalTrials.gov.
NCT01007240. Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel
NCT01039103. Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
NCT01041235. Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid
Tumors Who Have Failed Previous Therapies (Clinical Trial). ClinicalTrials.gov.
NCT01048008. Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in
Patients With Advanced Cancer (Clinical Trial). ClinicalTrials.gov.
NCT01050777. Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
NCT01050777. Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
NCT01051258. AeriSeal System for Lung Volume Reduction (Clinical Trial).
ClinicalTrials.gov.
NCT01052142. Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma (Clinical
NCT01054547. Topical Formulations of Liposomal Local Anesthetics (Clinical Trial).
ClinicalTrials.gov.
NCT01062204. AltrazealTM Versus Aquacel Ag for Partial Thickness Skin Donor Sites
NCT01066988. Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness
NCT01067131. Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent
Vulvovaginal Candida Infection (Clinical Trial). ClinicalTrials.gov.
NCT01073371. Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia
NCT01077765. Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy (Clinical Trial).
ClinicalTrials.gov.
NCT01088685. Hydrogel Blister Patch Prototype Treatment for Foot Blisters on the Heel
NCT01095848. A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive

Advanced Stage Ovarian, Breast and Prostate Cancer (Clinical Trial). ClinicalTrials.gov.
NCT01159028. Clinical Trial of L-Grb-2 Antisense Oligonucleotide in CML, AML, ALL &
MDS (Clinical Trial). ClinicalTrials.gov.
NCT01188226. Wear Characteristics of Denture Teeth (Clinical Trial). ClinicalTrials.gov.
NCT01190982. Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
NCT01191775. A Study of PNT2258 in Patients With Advanced Solid Tumors (Clinical Trial).
ClinicalTrials.gov.
NCT01206023. Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples
NCT01247818. Randomized Study of PH-10 for Psoriasis (Clinical Trial). ClinicalTrials.gov.
NCT01276548. A Trial to Evaluate Efficacy and Safety of the Combination Therapy of
Genexol-PM Plus Carboplatin Compared to Genexol Plus Carboplatin as a Firstline
Treatment in Subjects With Ovarian Cancer (Clinical Trial). ClinicalTrials.gov.
NCT01278095. Oral Bioavailability of GLPG0555 in Different Solid Formulations (Clinical
NCT01305512. Pharmacokinetic, Safety and Tolerability Study of Paclitaxel Injection
Concentrate for Nano-dispersion Administered Weekly (Clinical Trial). ClinicalTrials.gov.
NCT01334892. L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung
Transplant (LT) Patients (Clinical Trial). ClinicalTrials.gov.
NCT01359046. Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology (Clinical
NCT01519128. Drug Interaction Study Between Digoxin and TMC278 (Clinical Trial).
ClinicalTrials.gov.
NCT01556217. A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal
Fluid of Healthy Volunteers (Clinical Trial). ClinicalTrials.gov.
Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, et al. NK105, a paclitaxelincorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free
paclitaxel. Br J Cancer. 2006 Aug; 95(5): 6016.
Nektar | R&D Pipeline | Products in Development | Oncology | NKTR-102 (Website). Cited:
2010 Sep 26. Available from: http://www.nektar.com/product_pipeline/oncology_nktr102.html
Neopharm, Inc. Products - Neopharm (Website). Available from: www.neopharm.com/products/

NephroCare: Fresenius Polysulfone Helixone Dialysers (Website). Cited: 2011 May 11.
Available from:
http://www.nephrocare.com/global/en/products/fresenius_polysulfoner_helixoner_dialysers.ht
ml
Newman MS. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness
of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing
mice. Cancer Chemother.Pharmacol. 1999; 43(1): 1.
Nyman Y, Von Hofsten K, Palm C, Eksborg S, Lnnqvist PA. Etomidate Lipuro is associated
with considerably less injection pain in children compared with propofol with added
lidocaine. British Journal of Anaesthesia. 2006; 97(4): 536.
Nymox Pharmaceutical Corporation. Products Overview (Website). Cited: 2012 Mar 27.
Available from: http://www.nymox.com/default.action?itemid=12
Ocean NanoTech, LLC (Website). Cited: 2010 Sep 26. Available from:
http://www.oceannanotech.com/class.php?cid=31
OHagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against
influenza virus infection. Expert Review of Vaccines. 2007; 6(5): 699.
Okuda T, Kawakami S, Higuchi Y, Satoh T, Oka Y, Yokoyama M, et al. Enhanced in vivo
antitumor efficacy of fenretinide encapsulated in polymeric micelles. International journal of
pharmaceutics. 2009; 373(1-2): 1006.
Oncologic and Triton BioSystems Merge to Form Aduro BioTech (Website). Cited: 2010 Sep
26. Available from: http://www.fiercebiotech.com/press-releases/oncologic-and-tritonbiosystems-merge-form-aduro-biotech
Orexo AB - OX-NLA (Website). Cited: 2012 Mar 27. Available from:
http://www.orexo.com/en/Portfolio/OX-NLA/
OsSatura: Synthetic Bone Void Fillers (Website). IsoTis OrthoBiologics; 2004. Available from:
http://www.integra-ls.com/orthobiologics/pdf/OsSatura.pdf
Paciotti GF, Kingston DG., Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle
platform for developing multifunctional tumor-targeted drug delivery vectors. Drug
development research. 2006; 67(1): 4754.
Pagliaro M. Nano-Age: How Nanotechnology Changes Our Future. John Wiley & Sons; 2010.
Pannu J, Ciotti S, Eisma R, Ma L, Sutcliffe J. In vitro Susceptibility of Propionibacterium acnes
and Skin Permeation of NB-00X Formulations. Society for Investigative Dermatology, 69th
Annual Meeting (Website). 2009. Available from:
http://www.nanobio.com/news/documents/148098_616_11x17.pdf
Paul A, Vicent MJ, Duncan R. Using Small-Angle Neutron Scattering to Study the Solution
Conformation of (2-Hydroxypropyl) methacrylamide CopolymerDoxorubicin Conjugates.
Biomacromolecules. 2007 May; 8(5): 15739.
Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, et al. Diagnosing lung cancer in
exhaled breath using gold nanoparticles. Nature nanotechnology. 2009; 4(10): 66973.
Pevion Biotech AG | Virosome Pevion.com (Website). Cited: 2012 Mar 27. Available from:
http://www.pevion.com/index.php?page=732
Pharmos Corporation - Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion
Cream (Website). Pharmos, Inc. Cited: 2012 Mar 27. Available from:
http://investors.pharmoscorp.com/releasedetail.cfm?releaseid=218595
Plasmachem // Nanomaterials, NanoDiamonds (Website). Cited: 2010 Sep 26. Available from:
http://www.plasmachem.com/nanodiamonds.html
Platypus Technologies | Optically Transparent Polyurethane Substrates (Website). Cited: 2010
Sep 26. Available from: http://www.platypustech.com/transpsubstrates.html
Powell J, Nugent D, Harrison J, Soni A, Luk A, Stass H, et al. Safety and pharmacokinetics of a
recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of
Thrombosis and Haemostasis. 2008; 6(2): 27783.
Prashar J, Sharp P, Scarffe M, Cornell B. Making lipid membranes even tougher. J. Mater. Res.
2011 Jan; 22(08): 218994.
Premise Dental Composite from Kerr Corporation (Website). Sybron Dental Specialties, Inc.
Cited: 2012 Mar 27. Available from: http://www.kerrdental.com/index/kerrdental-compositespremise-2
Qdot Nanocrystal Technology Overview (Website). 2010. Available from:
http://www.invitrogen.com/site/us/en/home/brands/Molecular-Probes/Key-Molecular-ProbesProducts/Qdot/Technology-Overview.html
Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, Cripe TP. Cancer-Selective Targeting and
Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein. Clinical Cancer Research.
2009; 15(18): 5840 5851.
Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials.
Biotechnology Advances. 2009 Jan; 27(1): 7683.
Rainbow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, et al. Itraconazole IV
nanosuspension enhances efficacy through altered pharmacokinetic in the rat. Int. J. Pharm.
2007; 339: 25160.
Rauschmann MA. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable

composite carrier material for local delivery of antibiotics in bone infections. Biomaterials.
2005; 26(15): 2677.
Rossi JJ. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther. 2006; 13(7): 583.
Roszek B, Jong WH, Geertsma RE. Nanotechnology in medical applications: state-of-the-art in
materials and devices. 2005.
Roszek B. Nanotechnology in medical devices. Presentation.
Rudin CM. Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing
in Patients with Advanced Solid Tumors. Clinical cancer research. 2004; 10(21): 7244.
Saia Cereda CM, Tfoli GR, de Brito Junior RB, de Jesus MB, Fraceto LF, Groppo FC, et al.
Stability and local toxicity evaluation of a liposomal prilocaine formulation. Journal of
Liposome Research. 2008; 18(4): 32939.
Saladax Biomedical | Product Pipeline Assays (Website). Cited: 2010 Sep 26. Available from:
http://www.saladax.com/product-pipeline-assays-0
Sankhala KK, Mita AC, Adinin R, Wood L, Beeram M, Bullock S, et al. A phase I
pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J. Clin.
Oncol. 2009; 27: 15s.
Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, et al. Efficacy of oral
cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrobial agents and
chemotherapy. 2000; 44(9): 2356.
Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, et al. Inhibition of vessel
permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 2005; 7(3):
25161.
Sato M, Sambito MA, Aslani A, Kalkhoran NM, Slamovich EB, Webster TJ. Increased
osteoblast functions on undoped and yttrium-doped nanocrystalline hydroxyapatite coatings
on titanium. Biomaterials. 2006; 27(11): 235869.
Schettini D, Costa Val A, Souza L, Demicheli C, Rocha O, Melo M, et al. Pharmacokinetic and
parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted
to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Brazilian
journal of medical and biological research. 2005; 38(12): 187983.
Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the
camptothecinpolymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother
Pharmacol. 2005 Aug; 57(5): 65462.
Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH., Alabi CA, et al. Pharmacokinetics and
tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological
measurements. Proceedings of the National Academy of Sciences. 2009; 106(27): 11394.
Schmid G, Bumle M, Geerkens M, Heim I, Osemann C, Sawitowski T. Current and future
applications of nanoclusters. Chemical Society Reviews. 1999; 28(3): 17985.
Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, et al. Molecular
MR imaging of melanoma angiogenesis withavB3-targeted paramagnetic nanoparticles.
Magn. Reson. Med. 2005 Mar; 53(3): 6217.
Schwartz JA. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic
canine model. Cancer Res. 2009; 69(4): 1659.
Senior Staff Writer. Endo, SkyePharma Cease Propofol IDD-D Agreement (Website).
BioWorldToday; 2009. Available from: http://www.allbusiness.com/legal/health-care-lawdrug-medical-devices-approval-fdas/13399651-1.html
Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug
targeting: phase I evaluation of polymer-bound doxorubicin. Journal of clinical oncology.
2002; 20(6): 1668.
Shaffer SA, Baker-Lee C, Kennedy J, Lai MS, Vries P, Buhler K, et al. In vitro and in vivo
metabolism of paclitaxel poliglumex: identification of metabolites and active proteases.
Cancer Chemother Pharmacol. 2006 Aug; 59(4): 53748.
Shah P. Nanoemulsion: A pharmaceutical review. Systematic Reviews in Pharmacy. 2010; 1(1):
24.
Sheikhnejad R. MicroDNAs (MIDs) and Transcriptional Regulation. Nature precedings. 2009
Nov.
Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, et al. Development of Targeted
Therapy with Paclitaxel Incorporated into EGF-Conjugated Nanoparticles. Anticancer Res.
2009 Apr 1; 29(4): 100914.
Silence Therapeutics (Website). Cited: 2010 Sep 26. Available from: http://www.silencetherapeutics.com/content/therapeuticplatform/deliverytechnology.htm
SilvaGard: Antimicrobial Silver Nanotechnology Treatment for Medical Devices (Website).
2005. Available from:
http://www.acrymed.com/pdf/SilvaGard%20Technical%20Summary.pdf
Soepenberg O, de Jonge MJA, Sparreboom A, de Bruin P, Eskens FALM, de Heus G, et al.
Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors.
Clinical Cancer Research. 2005 Jan 15; 11(2): 703 711.
Spies CKG. The efficacy of Biobon and Ostim within metaphyseal defects using the Goettinger
Minipig. Arch.Orthop.Trauma Surg. 2009; 129(7): 979.
Starpharma Holdings, Ltd. (Website). VivaGel. Cited: 2012 Mar 27. Available from:
http://www.starpharma.com/vivagel
SUN PHARMA ADVANCED RESEARCH COMPANY (Website). Nanoparticle Technology.
Cited: 2012 Mar 27. Available from: http://www.sunpharma.in/nanoparticle.htm
Supratek Pharma Inc. (Website). Cited: 2010 Sep 26. Available from:
http://www.supratek.com/index.php?pgID=87
Talon Therapeutics, Inc. (Website). Talon Product Portfolio. Cited: 2012 Mar 27. Available
from: http://www.talontx.com/pipeline.php
Tekmira | Products (Website). Cited: 2012 Mar 27. Available from:
http://www.tekmirapharm.com/Programs/Products.asp#plk1
Tetric Evo Ceram (Ivoclar Vivadent North America) (Project #07-015) (Website). 2008.
Available from:
http://airforcemedicine.afms.mil/idc/groups/public/documents/afms/ctb_109677.pdf
Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee JS, Smith ND, et al. Nanoparticle-based
bio-barcode assay redefines undetectable PSA and biochemical recurrence after radical
prostatectomy. Proceedings of the National Academy of Sciences. 2009; 106(44): 18437.
Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes
target angiogenic endothelial cells in tumors and chronic inflammation in mice. Journal of
Clinical Investigation. 1998; 101(7): 1401.
TLC - Product (Website). Cited: 2011 Mar 31. Available from:
http://www.tlcbio.com/en/product.html
Trop M. Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms
in burn patient. J.Trauma. 2006; 60(3): 648.
US Patent Application: 09/767,367. Deffenbaugh BW, Herr HM, Pratt GA, Wittig MB.
Electronically controlled prosthetic knee. 2004. Cited: 2011 Mar 31.
US Patent: 5980551. Summers DP, See JR. Composition and method for making a biodegradable
drug delivery stent (Website). 1999.
US Patent: 7223770 . Zhang Y, Gold LC. Tocopherol-modified therapeutic drug compounds.
2007.
US Patent: US20090176813. Baert LEC, Dries WAMC, Schueller LB, Francois MKJ,
Remoortere PJMV. Aqueous Suspensions of Tmc278.
Veridex, LLC, a Johnson & Johnson company in vitro diagnostics oncology (Website). Cited:
2010 Sep 26. Available from:
http://www.veridex.com/cellsearch/csproducts/cellsearchepithelialkit.aspx
Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nature
Biotechnology. 2006; 24(10): 12118.
Wagner V, Hsing B, Gaisser S, Bock AK. Nanomedicine: Drivers for development and possible
impacts. JRC-IPTS, EUR. 23494.
Wang Y-X, Hussain S, Krestin G. Superparamagnetic iron oxide contrast agents:
physicochemical characteristics and applications in MR imaging. European Radiology. 2001
Nov; 11(11): 231931.
Welcome to Bexion Pharmaceuticals (Website). Cited: 2010 Sep 26. Available from:
http://www.bexionpharma.com/
Wiedenmann N. 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and
Therapeutic Gain. Clinical cancer research. 2007; 13(6): 1868.
Wilson RJ, Hu W, Fu CWP, Koh AL, Gaster RS, Earhart CM, et al. Formation and properties of
magnetic chains for 100 nm nanoparticles used in separations of molecules and cells. J Magn
Magn Mater. 2009 May 1; 321(10): 14528.
Wong YWH, Yuen CWM, Leung MYS, Ku SKA, Lam HLI. Selected Applications of
Nanotechnology in Textiles. AUTEX Research Journal (Website). 2006 Mar; 6(1). Available
from: http://www.freewebs.com/jayaramco/doc/Selected_Appz_of_Nanotechnology_in_Textiles.pdf
Xie X. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging
models. Cancer cell. 2007; 12(1): 52.
Yang H, Kao WJ. Dendrimers for pharmaceutical and biomedical applications. Journal of
Biomaterials Science, Polymer Edition, 17. 2006; 1(2): 319.
Yu JJ. Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin.
J.Drug Target. 2007; 15(4): 279.
Zamboni WC. Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents.
Oncologist. 2008 Mar 1; 13(3): 24860.
Zhang JA. Development and characterization of a novel Cremophor EL free liposome-based
paclitaxel (LEP-ETU) formulation. European journal of pharmaceutics and biopharmaceutics.
2005; 59(1): 177.
Zhang JA. Development and characterization of a novel liposome-based formulation of SN-38.
Int.J.Pharm. 2004; 270(1-2): 93.
Zhang X, Bowen C, Gareua P, Rutt B. Quantitative Analysis of SPIO and USPIO Uptake Rate
by Macrophages: Effects of Particle Size, Concentration, and Labeling Time. Proc. Intl. Soc.
Mag. Reson. Med. 2001; 9.
Zhang Z, Dunn MF, Xiao TD, Tomsia AP, Saiz E, CT ICF. Nanostructured hydroxyapatite
coatings for improved adhesion and corrosion resistance for medical implants. 2001;
Zuo L, Wei W, Morris M, Wei J, Gorbounov M, Wei C. New technology and clinical
applications of nanomedicine. Medical Clinics of North America. 2007;91 (5): 84562.

Nano Drugs

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Nano Drugs

Uploaded by

Copyright:

Available Formats

Supplementary Material Complete Listing of Results:

Table SM.1. Potential nanomedicine therapeutic products.

Listed Company / Sponsor

FDA Application Number or

Wagner, Project, Bawa, Faraji,

Wagner, Bawa, Griese

Wagner, Bawa, Faraji

SEQUUS Pharmaceuticals Inc.

Wagner, Bawa, Faraji

Wagner, Faraji, NCT00556946,

Wagner, Project, Bawa, Faraji,

Influenza A (H1N1) pandemic vaccine suspension. Administered intravenously.

AMAG Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

Peripheral Vascular Disease

Wagner, Bawa, Glck

The Liposome Company, Inc.

Swine-Origin Influenza A H1N1 Virus

Hana Biosciences, Inc

Azaya Therapeutics, Inc.

Aleku, Li L, Silence Therapeutics

Hana Biosciences, Inc

Bawa, NCT00689065, Heidel

Cyclodextrin-containing siRNA delivery nanoparticles based on Calando's RNAi/Oligonucleotide

Mymetics / Pevion Biotech Ltd

Hepatitis B/C, Cancer

Yakult Honsha Co., LTD

Juvaris BioTherapeutics, Inc.

Liposomal mitoxantrone HCL (Novantrone). Based on NeoPharm's proprietary NeoLipid liposomal

NCT00747474, Huang, TLC

Taiwan Liposome Company

Lipotek Pty Ltd

Hamaguchi, Matsumura (2005),

Mitsubishi Tanabe Pharma Corporation

NanoCarrier Co., Ltd.

NCT00445419, Pevion, Huckriede

Pevion Biotech Ltd

Pevion Biotech Ltd

NCT01067131, Pevion, Huckriede

Pevion Biotech Ltd

Recurrent Vulvovaginal Candidiasis

Matsumura (2007), Seymour

Pharmacia & Upjohn Inc.

ProNAi Therapeutics Inc.

NCT01054547, Ribeiro de Araujo

University of Campinas, Brazil

NCT00385177, US Patent 7223770

Tekmira Pharmaceuticals Corporation

Stable-Nucleic-Acid-Lipid-Particles (SNALPs). Pegylated, liposomal delivery of small interefering RNA

Tibotec Pharmaceuticals Ltd

Debbage, Dobrovolskaia, Schluep

Cerulean Pharma, Inc.

NCT00964080, Matsumura (2007),

Mebiopharm Co., Ltd

Description / Additional Details

Palmitate alprostadil nanoemulsion intravenously injected for treatment of peripheral vascular

Liposomal camptothecin. Intravenously injected anti-cancer chemotherapy drug.

Camptothecin conjugated with Mersana's proprietary Fleximer technology. Fleximer is a

Table SM.1. Potential nanomedicine therapeutic products.

Listed Company / Sponsor

Matsumura (2009), NanoCarrier

NanoCarrier Co., Ltd.

Bawa, NCT00356980, Paciotti